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ABSTRACT OF DISSERTATION

HUMAN BUTYRYLCHOLINESTERASE MUTANTS FOR COCAINE
DETOXIFICATION
Cocaine is one of the most reinforcing drugs of abuse and has caused serious
medical and social problems. There is no FDA-approved medication specific for cocaine.
It is of a high priority to develop an effective therapeutic treatment for cocaine abuse.
Human butyrylcholinesterase (BChE) has been recognized as a promising candidate of
enzyme therapy to metabolize cocaine into biologically inactive metabolites and prevent
it from reaching central nervous system (CNS). However, the catalytic activity of widetype human BChE against cocaine is not sufficiently high for treatment of cocaine abuse.
Dr. Zhan’s lab has successfully designed and discovered a series of high-activity mutants
of human BChE specific for cocaine metabolism.
This dissertation is mainly focused to address the possible concerns in further
development of promising human BChE mutants for cocaine detoxification, including
whether the administration of this exogenous enzyme will affect the cholinergic system,
whether it can efficiently hydrolyze cocaine’s toxic metabolites, and whether the
commonly used therapeutic agents will significantly affect the catalytic activity of the
BChE mutants against cocaine when they are co-administered. According to the results
obtained, all of the examined BChE mutants have a considerably improved catalytic
efficiency against (-)-cocaine, without significantly improving the catalytic efficiency
against any of the other examined substrates, including neurotransmitter acetylcholine.
Two representative mutants (including E12-7) also have a considerably improved
catalytic activity against cocaethylene (formed from combined use of cocaine and alcohol)
compared to wild-type BChE, and E12-7 can rapidly metabolize cocaethylene, in
addition to cocaine, in rats. Further evaluation of possible drug-drug interactions between
E12-7 and some other commonly used therapeutic agents revealed that all of the
examined agents, except some tricyclic antidepressants, do not significantly inhibit E12-7.
In addition, an effort to discover new mutants with further improved activity against
cocaine led to the discovery of a new BChE mutant, denoted as E20-7, according to both
the in vitro and in vivo assays. The encouraging outcomes of the present investigation
suggest that it is possible to develop a more effective enzyme therapy for cocaine abuse
treatment using one of the most promising BChE mutants, such as E12-7 or E20-7.

KEYWORDS: Protein drug, enzyme therapy, human butyrylcholinesterase, cocaine, and
drug abuse treatment.

Shurong Hou
Student’s Signature
7/31/2014
Date

HUMAN BUTYRYLCHOLINESTERASE MUTANTS FOR COCAINE
DETOXIFICATION

by
Shurong Hou

Chang-Guo Zhan
Director of Dissertation
Jim Pauly
Director of Graduate Studies
7/31/2014
Date

ACKNOWLEDGEMENTS

I would like to show my greatest appreciation to all the people who have supported
and helped during my graduate studies at University of Kentucky. Without them, I would
never have been able to complete my study and dissertation.
First of all, I would like to express my deepest gratitude to my advisor Dr. ChangGuo Zhan for his guidance, understanding, and encouragement. He is always there
whenever I met any kind of problems, which makes me feel warm and secure. I learned a
lot from him, especially on critical thinking and problems solving, which will benefit my
future career and whole life. I would like to thank Dr. Kyung-Bo Kim, Dr. Todd Porter,
and Dr. Sharon Walsh for serving as my dissertation committee members, giving me
suggestions throughout my study. I would also like to thank Dr. Zhenyu Li for serving as
the outside examiner of my dissertation defense. Besides, I am also very grateful to Dr.
Fang Zheng for her support, guidance, and advice on the research projects, parenting, and
others as the co-principal investigator and a friend.
My sincere thanks also go to all the former and present members of Dr. Zhan's lab
for their helps in experiments and their valuable friendship, especially Mr. Max Zhan and
Dr. Lei Fang for their contributions in computational modelling part in my dissertation;
Dr. Wenchao Yang and Dr. Liu Xue for their help and the enjoyable cooperation with
them; Ms. Min Tong and Mr. Xiabin Chen for their instructive discussions and
inspirations; Dr. Zhenyu Jin for producing enzyme materials for in vivo studies. I also
thank Ms. Catina Rossoll for her kind help throughout my graduate studies.
Last but not least, I would like to thank my parents for their love, sacrifice and
support during my whole life. I would also thank my husband Lei who is always there
with me getting through the hard time and patiently tolerant my occasional willfulness.
Finally, I would like to specially thank my son Kevin who has been inspiring me to work
hard for my career development.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................... iii
TABLE OF CONTENTS ................................................................................................... iv
LISTS OF FIGURES ......................................................................................................... vi
LIST OF TABLES ........................................................................................................... viii
Chapter One: Cocaine Abuse and its Therapeutic Treatment ............................................. 1
1.1 Cocaine and its abuse ................................................................................................ 1
1.2 Mechanism of cocaine action and cocaine-induced toxicity .................................... 2
1.3 Pharmacotherapy for cocaine abuse — pharmacodynamic approach ...................... 5
1.4 Pharmacotherapy for cocaine abuse — pharmacokinetic approach ......................... 9
1.5 Human BChE as a potential therapeutic enzyme for treatment of cocaine abuse .. 14
1.6 Further development of the therapeutic enzymes ................................................... 15
Chapter Two: Substrate Selectivity of High-Activity Mutants of Human
Butyrylcholinesterase ........................................................................................................ 17
2.1 Significance of substrate selectivity of the human BChE mutants ......................... 17
2.2 Computational methods .......................................................................................... 18
2.3 Experimental methods ............................................................................................ 21
2.4 Insights from molecular modeling .......................................................................... 22
2.5 Kinetic parameters .................................................................................................. 28
2.6 Conclusion .............................................................................................................. 37
Chapter Three: Kinetic Characterization of Human Butyrylcholinesterase Mutants for
Hydrolysis of Cocaethylene .............................................................................................. 38
3.1 Overview of possible treatment of combined cocaine-alcohol abuse using highactivity mutants ............................................................................................................. 38
3.2 Materials and methods ............................................................................................ 41
3.3 Insights from molecular docking ............................................................................ 45
3.4 Kinetic parameters .................................................................................................. 47
3.5 Cocaethylene clearance accelerated by E12-7 ........................................................ 52
3.6 Effects of E12-7 on the pharmacokinetics of (-)-cocaine and cocaethylene .......... 55
3.7 Conclusion .............................................................................................................. 62
Chapter Four: Evaluation of the Catalytic Activity of E12-7 against Cocaine in the
Presence of Commonly Used Small-Molecule Drugs ...................................................... 63
4.1 The importance of drug-enzyme interaction study ................................................. 63
4.2 Materials and methods ............................................................................................ 64
4.3 Drug-E12-7 interaction ........................................................................................... 66
4.4 Inhibitory activities of compounds for E12-7 ......................................................... 72
4.5 Conclusion .............................................................................................................. 74
Chapter Five: Characterization of a Highly Efficient New Mutant of Human
Butyrylcholinesterase Specific for Cocaine Detoxification .............................................. 75
iv

5.1 Overview of the strategy to design and discover high-activity mutants of human
BChE ............................................................................................................................. 75
5.2 In vitro characterization of E20-7 for their activities against (-)-cocaine and
acetylcholine ................................................................................................................. 77
5.3 In vivo characterization of E20-7 for its potency in metabolizing cocaine............. 82
5.4 Conclusion .............................................................................................................. 93
Chapter Six: Concluding Remarks and Future Plan ......................................................... 95
6.1 Summary of the major conclusions obtained from this investigation..................... 95
6.2 Future plan of this investigation ............................................................................. 96
REFERENCE .................................................................................................................... 98
VITA ............................................................................................................................... 110

v

LISTS OF FIGURES
Figure 1.1 Molecular structure of (-)-cocaine free base. .................................................... 1
Figure 1.2 Cocaine metabolic pathways in human. .......................................................... 13
Figure 2.1 The energy-minimized ES and TS1 structures for (-)-cocaine interacting with
wild-type human BChE and E12-7. ................................................................ 23
Figure 2.2 The energy-minimized ES and TS1 structures for (+)-cocaine interacting with
wild-type human BChE and E12-7. ................................................................ 25
Figure 2.3 The energy-minimized ES and TS1 structures for ACh interacting with wildtype human BChE and E12-7. ........................................................................ 26
Figure 2.4 The energy-minimized ES and TS1 structures for ATC interacting with wildtype human BChE and E12-7. ........................................................................ 27
Figure 2.5 The energy-minimized ES and TS1 structures for BTC interacting with wildtype human BChE and E12-7. ........................................................................ 28
Figure 2.6 Kinetic data for (-)-cocaine hydrolysis catalyzed by wild-type human BChE
and various BChE mutants.............................................................................. 29
Figure 2.7 Kinetic data for (+)-cocaine hydrolysis catalyzed by wild-type human BChE
and various BChE mutants.............................................................................. 30
Figure 2.8 Kinetic data for ACh hydrolysis catalyzed by wild-type human BChE and
various BChE mutants. ................................................................................... 31
Figure 2.9 Kinetic data for ATC hydrolysis catalyzed by wild-type human BChE and
various BChE mutants. ................................................................................... 32
Figure 2.10 Kinetic data for BTC hydrolysis catalyzed by wild-type human BChE and
various BChE mutants. ................................................................................... 33
Figure 3.1 Cocaine metabolites produced in humans through hydrolysis by BChE,
oxidation by cytochrome P450 (CYP) 3A4, and reaction of cocaine with
alcohol ............................................................................................................. 39
Figure 3.2 Reaction scheme and kinetic equations used in the kinetic modeling. ............ 44
Figure 3.3 Docked structures of the wild-type BChE and E12-7 binding with
cocaethylene and (-)-cocaine .......................................................................... 47
Figure 3.4 UV–visible absorptions of the enzyme and substrates. (A) UV-Vis absorption
of (-)-cocaine, cocaethylene, and E12-7. ........................................................ 48
Figure 3.5 Kinetic data obtained in vitro for enzymatic hydrolysis of (-)-cocaine and
cocaethylene .................................................................................................... 50
Figure 3.6 Kinetic data obtained in vitro for E14-3-catalyzed hydrolysis of (-)-cocaine in
the absence and presence of alcohol ............................................................... 52
Figure 3.7 Cocaethylene clearance accelerated by E12-7. ............................................... 54
Figure 3.8 Kinetics of (-)-cocaine and its metabolites in the presence of alcohol and
various enzymes. ............................................................................................. 57
Figure 3.9 The modeled concentrations (in silico data) of (-)-cocaine, cocaethylene, and
norcocaine in human blood when the initial concentrations of (-)-cocaine,
cocaethylene, and norcocaine are 61, 34, and 5 M, respectively. ................ 61
Figure 4.1 Chemical structures of doxepin, amitriptyline, and nortriptyline. ................... 72
Figure 5.1 Kinetic data for (-)-cocaine (A) and ACh (B) hydrolysis catalyzed by E20-7.80
Figure 5.2 Cocaine (i.v. administrated) clearance accelerated by E20-7.......................... 86
vi

Figure 5.3 Cocaine (i.p. administrated) clearance accelerated by E20-7.......................... 88
Figure 5.4 Potency of protection effects of E20-7 against acute toxicity of a lethal dose of
cocaine. ........................................................................................................... 90
Figure 5.5 Effects of the exogenous enzyme E20-7 on cocaine-induced hyperactivity. .. 92

vii

LIST OF TABLES

Table 1.1 Inhibition constants of cocaine against interacting proteins. .............................. 5
Table 2.1 Kinetic parameters determined for (-)-cocaine, (+)-cocaine, ACh, ATC, and
BTC hydrolyses catalyzed by wild-type BChE and its mutants. ...................... 34
Table 3.1 Kinetic parameters determined in vitro for (-)-cocaine, norcocaine and
cocaethylene hydrolyses catalyzed by wild-type BChE and its mutants. ......... 51
Table 3.2 Kinetic parameters obtained from in silico modeling for (-)-cocaine and
norcocaine hydrolyses catalyzed by wild-type human BChE and its mutants. 59
Table 4.1 Class I drug concentrations and tested interactions with E12-7. ...................... 67
Table 4.2 Class II drug concentrations and tested interactions with E12-7. ..................... 68
Table 4.3 Class III drug concentrations and tested interactions with E12-7. ................... 70
Table 4.4 Class IV drug concentrations and tested interactions with E12-7. ................... 71
Table 4.5 IC50 and inhibitory constant Ki of compounds for E12-7. ................................ 73
Table 5.1 Kinetic parameters determined in vitro for enzymatic hydrolysis of (-)-cocaine
and ACh. ........................................................................................................... 81

viii

Chapter One: Cocaine Abuse and its Therapeutic Treatment

1.1 Cocaine and its abuse
Cocaine is a powerfully addictive drug that primarily acts on the brain.(1) Pure
cocaine was originally extracted from the leaves of coca plant which grows in South
America, mainly in Peru, Bolivia and Colombia.(2) Coca leaves have been chewed and
ingested for at least 8,000 years, while the purified cocaine has been an abused substance
for over 100 years.(2) This alkaloid was first purified from coca leaves in 1855 by the
German chemist Friedrich Gaedcke (3) and first characterized chemically in 1859 by
Albert Niemann (4, 5). Cocaine was proposed as a ―wonder drug‖, once becoming the
cure for opium, morphine, and alcohol problems by the 1860s, and first brought into
clinical use as a local anesthetic in 1884 by Karl Koller.(6) As a result of its medical use,
cocaine gained great popularity by the end of 19th and the beginning of 20th century. It
was one of the first alkaloids to be chemically synthesized. The total synthesis of cocaine
was confirmed by Richard Willstätter and his colleagues in 1923, while the full
stereochemistry of cocaine molecule was not clear until E. von Hardeggar and Hans Ott
figured it out in 1955.(2) As cocaine gained popularity and its uncovered properties,
society became alarmed over its addictive potential and other effects on humans. Because
of this, its use was under strict regulations by the beginning of 20th century.(6)

Figure 1.1 Molecular structure of (-)-cocaine free base.

Cocaine is abused in two forms: the water-soluble hydrochloride salt, and the waterinsoluble cocaine free base. The salt can be taken orally, snorted (intranasal), or
injected.(7) The high melting temperature (190ºC) of the salt makes it unsuitable for
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smoking because it will decompose before vaporization. The free base can be smoked or
snorted. The relatively low melting temperature (98ºC) makes it suitable for smoking.(8)
Onset of effects, peak effects, duration of euphoria, and plasma half-life of cocaine
are affected by route of administration and dosage. Cocaine can take effect in from less
than one minute to around 15 minutes and last for 15 minutes to one hour, depending on
the actual dose.(9) The faster the drug is absorbed, the earlier and stronger the resulting
euphoric effects, however, the shorter the effects last. Compared with oral and intranasal
use of cocaine, the effects of intravenous and smoked cocaine are rapid and short-lived.
The severity of cocaine dependence is also associated with the route of administration.
Intravenous injection of cocaine correlates with the highest levels of dependence;
intranasal use correlates with the lowest levels, and crack smoking is intermediate
between the two.(10)
In general, after cocaine is taken, the users feel rapid and intense high. The high is
relatively short and followed by a coming down period, which makes the users repeat the
use for high and, leading to addiction. Besides the feeling of euphoria, effects of cocaine
also include feeling of energetic, talkative, increased alertness, reduced appetite, and
sensation of light, sound and touch.(1) Once addicted to cocaine, the risk of adverse
psychological or physiological effects increases. It can lead to increased irritability,
restlessness, panic attacks, and paranoia—even hallucinations. Long-term use of cocaine
could cause serious physical problems, including cardiovascular failures, respiratory
difficulties, and gastrointestinal complications, and mental problems, including
depression, agitation, nervous, and tired but unable to sleep.(11) Cocaine overdose could
be more serious and even lethal, due to the possible respiratory failure, heart-failure,
stroke, or seizures induced by cocaine’s toxicity.(12, 13)

1.2 Mechanism of cocaine action and cocaine-induced toxicity
The pharmacology of cocaine is complicated and involves several organ systems,
primarily complicates the brain, heart, and lung. Cocaine-protein interaction is the
foundation that affects all these systems. Cocaine binds to several proteins, including
monoamine transporters, neurotransmitter receptors, plasma proteins, and voltage gated
ion channels in central and periphery nervous systems.(14)
2

1.2.1 Reinforcing effects and cocaine addiction
Cocaine is a powerful addictive drug, causing its reinforcing and toxic effects in
CNS by binding with monoamine transporters, especially dopamine transporter (DAT).(1,
14-17) Cocaine acts primarily as a dopamine transporter blocker in the rewarding center
of CNS.(15, 17) The brain’s key areas involved in reward lies in a region of the midbrain
called the ventral tegmental area (VTA) and extended to a region known as the nucleus
accumbens. During the normal dopaminergic signaling cycle, neurotransmitter dopamine
(DA) is released into synaptic cleft from the transmitting neuron and binds with
dopamine receptors on the receiving neuron to conduct the signaling. Dopamine will be
then recycled via DAT located on the transmitting neuron to end the signaling cycle.
However, cocaine entering into the brain would interfere with this signaling cycle. It will
bind with the DAT to form a complex that block the binding of dopamine.(18) This can
result in accumulation of dopamine in the synaptic cleft and lead to the prolonged and
enhanced effect of dopaminergic signaling, which causes the euphoria feeling as reported
by cocaine users. The DAT is responsible for the major psychostimulant and reinforcing
effects of cocaine.(14)
Moreover, chronic use of cocaine changes the structure and function of brain. It is
reported that one-time use of cocaine could cause the change of the dopaminergic
signaling, i.e. the down-regulation of dopamine receptors and up-regulation of dopamine
transporter for at least months.(1, 19, 20) Therefore, cocaine users would not achieve the
same ―high‖ as they felt at the first time they used the drug, leading to the development of
cocaine addiction. Once developed, it is very hard to get rid of due to the change is
usually an extremely slow process to recover. During the addiction development, patients
first feel impulsive to take cocaine (positive reinforcement), and soon become
compulsive because of negative emotional state (negative reinforcement).(21, 22) They
reported anxiety, dysphoria and irritability when cocaine is not available.
Besides DAT, Cocaine also interacts with other transporters, including the serotonin
transporter (SERT), and the norepinephrine transporter (NET).(14, 23, 24) The
GABAergic system and the NMDA-glutamate systems are also intimately involved in
cocaine toxicity.(25) Although cocaine does not directly interact with the GABA receptor,
GABA is the most important neurotransmitter which could be manipulated for treatment
3

of cocaine abuse.(14)

1.2.2 Acute toxicity and cocaine overdose
Besides three monoamine transporters in CNS, cocaine also binds with
norepinephrine transporter, muscarinic acetylcholine and sigma receptors, and several
voltage-gated ion channels in periphery nervous system.(14) The inhibition constant (Ki)
of cocaine for proteins, including transporters, receptors, and ion channels, are
summarized in Table 1.1. The cocaine concentration in human body in the case of cocaine
overdose is much higher than it in the case of cocaine addiction. Therefore, as the cocaine
concentration increases, proteins with high affinities for cocaine will be saturated, and
cocaine will start to bind to proteins with lower affinities. Those interactions contribute to
the acute toxicity of cocaine.
The classic signs of cocaine overdose include increased heart rate, increased body
temperature, elevated blood pressure, and chest pain. Besides, it can also cause
cardiovascular effects (heart attacks), neurological effects (seizures), and gastrointestinal
complications (abdominal pain and nausea).(26) Cocaine-related deaths generally result
from cardiac arrest or seizures, and the followed respiratory failure.
Most of the cardiac toxicity of cocaine can be attributed to two basic mechanisms:
one is its ability to interact with all three ion channels, leading to a local anesthetic effect;
the second is its ability to block reuptake of norepinephrine in the presynaptic neurons in
the central and peripheral nervous systems, resulting in increased catecholamines and
sympathetic output.(27)
There are some conflicting data concerning the effects of muscarinic acetylcholine
and sigma receptors on the convulsion and lethality effects of cocaine.(14) Therefore,
their contributions to cocaine-induced toxicity are still unclear.

4

Table 1.1 Inhibition constants of cocaine against interacting proteins.(14)
Protein

Ki (M)

Dopamine transporter

0.64

Serotonin transporter

0.14

Norepinephrine transporter

1.6

Muscarinic acetylcholine receptor (rat)

19, 24, 40

Sigma receptor (rat)

6.7

Cardiac myocyte sodium channel

8

Cardiac potassium rectifier channel

5.6

1.3 Pharmacotherapy for cocaine abuse — pharmacodynamic approach
1.3.1 Cocaine addiction
Medication-assisted pharmacotherapy and behavioral therapy are commonly
employed in drug addiction treatment. Pharmacotherapy for cocaine abuse includes
pharmacodynamic

and

pharmacokinetic

approach.

Because

the

traditional

pharmacodynamic approach has been successful in the treatment of opioid and nicotine
dependence (28), it was also extensively studied for cocaine abuse treatment.
Pharmacodynamic approach is to develop a small molecule targeting a speciﬁc
transporter/receptor to manipulate various neurotransmitter systems in order to block
cocaine’s effects, such as dopaminergic, serotoninergic, noradrenergic, cholinergic,
glutamatergic, GABAergic, and opioidergic pathways.(29) As the neurochemistry and
neurobiology of drug dependence progress recently, various compounds have been tested
in clinical studies to interfere with cocaine’s action, including the drugs approved for
other diseases. However, due to ineffectiveness and/or unwanted side effects and/or its
potential addiction tendency, no ideal pharmacodynamic agent specific for cocaine abuse
treatment has been identified yet.

1.3.1.1 Compounds targeting the dopamine system
Many studies have indicated that dopaminergic system is intimately involved in
drug reward and addiction.(30, 31) Almost all the addictive drugs, including cocaine,
heroin, nicotine, and alcohol, have been shown to directly stimulate the dopaminergic
5

system by increasing extracellular DA in the nucleus accumbens through different
mechanisms.(21, 30, 31) The increase in DA level has been thought to result in the
euphoria effects of abused drug.(16, 32) Based on this dopamine-based hypothesis, much
effort has been focused on manipulation of DA transmission in the brain reward system
by targeting DAT (agonist therapy), or DA receptors (antagonist therapy) in development
of cocaine addiction treatment.

Compounds targeting the dopamine transporter
Agonist or substitution therapies have proven effective in the treatment of opioid
and nicotine dependence.(28) Similarly, drugs that block the DAT, but are less addictive
than cocaine, might be promising for treatment of cocaine addiction as well. In fact, this
strategy has been in the leading place for more than a decade in the development of anticocaine medication. However, because the binding site of cocaine in DAT is overlapped
with the binding site of dopamine (18, 33, 34), it is very challenging to find a small
molecule that can block cocaine action on DAT without interfering the normal function of
DAT and the downstream signaling. Many DAT inhibitors have been developed, and
several of them have been tested on human, such as vanoxerine, methylphenidate and
modafinil. However, none of them have shown to be successful due to their own
significant abuse liability and/or adverse side-effects.(35)

Compounds targeting the dopamine receptor
Cocaine’s action in brain reward center is primarily mediated by elevation of
extracellular DA, followed by activation of postsynaptic DA receptors, and producing the
enhanced effect of dopaminergic signaling. Thus, blockade of DA receptors is another
therapeutic approach for cocaine addiction treatment. Among the five subtypes of DA
receptor in the brain, both D1 and D2 subtypes have shown their importance in
modulating actions of DA.(32) However, clinical trials using selective D1 or D2 receptor
antagonists for cocaine dependence treatment have failed due to ineffectiveness and/or
unwanted side-effects.(28) As a result, more efforts have switched to develop low
selective D1/2 receptor antagonists or D3 receptor antagonists, such as BP-897,
GSK598809, and ABT-925 for cocaine addiction treatment.(28)
6

1.3.1.2 Compounds targeting the serotonin system
As discussed earlier, besides its action on DAT, cocaine also binds with the
norepinephrine transporter (NET) and serotonin transporter (SERT), causing the
accumulation of those monoamines as well. Acute cocaine intoxication is characterized
by enhanced dopamine transmission and increased release of serotonin (36) while
cocaine withdrawal is characterized by decreased levels of serotonin in the nucleus
accumbens.(37) These evidences suggest the involvement of serotonin in cocaine reward
and reinforcement. Pharmacological manipulation of the serotonin system using selective
serotonin reuptake inhibitors and serotonin receptor antagonist for the treatment of
cocaine addiction showed mixed results, which needs further evaluation in clinical
study.(38)

1.3.1.3 Compounds targeting the GABAergic system
GABA is the major inhibitory neurotransmitter in CNS, and GABAergic neurons
can modulate brain dopaminergic reward functions. Significant evidences suggest that
GABA can inhibit cocaine-induced release of dopamine and reduce the reinforcing
effects of cocaine in animals, and increase of GABA activity in addicted brains leads to
decrease in drug craving and relapse.(15, 39) Much efforts have focused on two
approaches to increase GABAergic activity: (1) by inhibiting GABA transaminase, the
primary enzyme involved in metabolism of GABA, such as the irreversible inhibitor
vigabatrin; or (2) by directly stimulating GABA receptors with an agonist, including
benzodiazepines, tiagabine, topiramate, baclofen, and valproic acid.(29)
Although there is no direct interaction between cocaine and GABAergic system,
GABA is the most important target which could be manipulated for treatment of cocaine
abuse, according to the outcomes of recent preclinical and clinical studies.(14) One
proposed mechanism for the interaction between cocaine and GABA is that the activation
of dopamine D2 receptors by cocaine may decrease GABA release, which will cause
enhanced CNS excitation shown in cocaine-induced toxicity.(14) Benzodiazepines, are a
class of drugs for cocaine overdose treatment in emergency room. Benzodiazepines as the
agonists bind to a unique allosteric site on GABA receptor, and increase GABAergic
neurotransmission and the frequency of GABA-mediated chloride channel opening,
7

producing the CNS depression to relieve cocaine-induced toxicity.

1.3.1.4 Compounds targeting the glutamate system
L-glutamate acts as the major excitatory neurotransmitter in CNS through two
classes of glutamate receptors: ionotropic (iGluR) and metabotropic (mGluR) glutamate
receptors. Although the exact role of glutamate in modulating cocaine’s rewarding effects
remains unclear, more and more studies indicate that glutamate modulates cocaine-related
dopamine release and is intimately involved in relapse to drug-seeking behavior.(40, 41)
Various types of mGluR antagonist/agonist have been examined in the preclinical study
and also human clinical trials, such as N-acetylcysteine, a cystine prodrug to increase the
basal levels of extracellular glutamate; fenobam and MPEP as mGlu5 antagonists;
AZD8529 and LY404039 as mGlu2/3 agonists; memantine, and dizocilpine as NMDA
receptor antagonists.(28)

1.3.1.5 Compounds targeting the opioid system
The endogenous opioid peptides regulate and modulate dopaminergic function
within the brain reward center.(42) Three major classes of opioid receptors, μ, δ, and κ
become the targets for further manipulation. Candidate compounds which differentially
target opioid μ, δ, and κ receptors have been evaluated for possible anti-cocaine
medications. Naltrexone and naloxone, opioid μ receptor antagonists, approved for opioid
dependence and overdose treatment, are evaluated in preclinical study. Buprenorphine, a
partial opioid μ receptor agonist and opioid κ receptor antagonist, and enadoline, an
opioid κ receptor agonist, are evaluated on humans.(29)

1.3.2 Cocaine overdose
According to DAWN report released in 2012, cocaine misuse or abuse is the most
common cause of illicit drug-related Emergency Department (ED) visits in the US,
accounting for 488,101 ED visits in 2010.(43) Cocaine overdose could be potentially
lethal. The typical symptoms of cocaine overdose are high blood pressure, rapid heart rate,
and increased rate of breathing. The most frequent complaint by patients is cocaineassociated chest pain, accounting for 40% of cocaine-related ED visits.(44) Emergency
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Department treatments are mainly to relieve the chest pain and possible heart attack.
After the use of cocaine is confirmed by self-reports or by analysis of cocaine metabolite
in the urine, the cocaine users should be provided with intravenous fast-onset
benzodiazepines (diazepam and midazolam) as early management to counter agitation,
irritability, seizures, and hyperexcitable state. When patients do not calm down, sodium
nitroprusside, nitroglycerin, or phentolamine can be applied to relieve hypertension. If
patients show hyperthermia, cold water, fans, cooling blankets, and acetaminophen could
be given to the patients. If patients do not respond to benzodiazepines and vasodilators,
calcium channel blockers may be considered. Besides, if patients have had a true heart
attack (myocardial infarction), antiplatelet, such as aspirin and heparin could be given to
patients, and aspirin is recommended to be routinely administrated.(45, 46) Cocaine
blocks norepinephrine reuptake and lead to accumulation of norepinephrine. Excess
norepinephrine causes stimulation of both α- and β-adrenergic receptors. Clinically, the
use of a β-adrenergic antagonist in cocaine-overdosed patient has resulted in death.
Alternatively, α-adrenergic antagonist, such as phentolamine, can counter the
vasoconstrictive effects of cocaine, suggesting that the mechanism is cocaine-induced
elevation in α-adrenergic tone.(45)
To summarize, the existing ED protocol treat patients only by controlling symptoms
according to their complaints and clinical presentations, i.e. it only simply relieves the
cocaine-induced symptoms, instead of completely blocking cocaine’s effects.
―Recidivism is high among patients with cocaine-associated chest pain (60% admit to
cocaine use in the next year)‖(46), which may suggest that more effective medications
need to be developed to quickly detoxify large amount of cocaine and prevent it from
entering the brain.
1.4 Pharmacotherapy for cocaine abuse — pharmacokinetic approach
Most anti-addiction treatment has been using the traditional pharmacodynamic
approach for decades, i.e. to develop a small molecule binding with DAT or another
transporter/receptor to block cocaine’s action.(29) However, despite decades of efforts,
there is no FDA-approved medication specific for cocaine abuse so far.(47) Recently, the
alternative protein-based pharmacokinetic approach has drawn more and more attention,
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i.e. to develop an agent (an enzyme, antibody, or vaccine which producing an antibody in
the body) that can accelerate the metabolism of cocaine in the body and/or prevent the
delivery of cocaine from reaching CNS.(17, 48, 49) Protein-based agents would not cross
the blood brain barrier and, thus, would not enter the brain. So, they are not expected to
block the normal transporter and receptor functions. In particular, the enzyme therapy has
the advantage of higher efficiency over antibody and vaccine approaches, which makes
the enzyme therapy more appealing for cocaine abuse treatment. The feasibility of the
pharmacokinetic approaches for the treatment of cocaine addiction and overdose has been
discussed in detail in a recent review article (17).

1.4.1 Cocaine vaccine or antibody for treatment of cocaine dependence
It has been known that a small molecule (hapten), such as cocaine, will not evoke an
immune response unless covalently attached to an immunogenic protein (carrier).(50) To
be specific, it involves an antigen consisting of cocaine or cocaine-like molecular as the
hapten, covalently attached to the carrier protein with the aid of a functional linker, and
an adjuvant to stimulate the immune system’s response to the antigen. The conjugate will
be immunized to produce cocaine-specific antibody as well as the foreign protein-specific
antibody. Therefore, the immune system can generate antibodies that bind to cocaine.
When cocaine molecules are bound by anti-cocaine antibody in the bloodstream, cocaine
distribution will be altered between brain and plasma. Because the antibody-cocaine
complex is so large that it could not cross the blood/brain barrier, cocaine is prevented
from producing its reinforcing effects in brain. Antibody-bound cocaine is released
slowly, and can be metabolized by endogenous enzymes, especially human BChE, in the
blood or in tissues.(51)
Both active and passive immunization approaches have been investigated for
treatment of cocaine abuse.(52) Antibody in active immunization approach is naturally
produced by the antigen in recipient and stays active for a longer period of time in
months, whereas antibody in passive immunization is usually generated in another
species or in vitro and transferred to the recipient for cocaine binding, and can only be
stable for a period of time in weeks.
A cocaine vaccine/antibody shows two advantages over existing agonist approach
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for treatment of cocaine dependence. First, it does not require daily administration. A
cocaine vaccine could last for weeks or months. Second, because the antibodies do not
act in the brain so that they are likely to have fewer adverse effects than drugs acting in
the brain. It also has some potential disadvantages. The major disadvantage of the vaccine
/antibody strategy is its low efficiency due to the fact that each antigen-binding site of the
antibody can bind with only one cocaine molecule. It will not completely block the
effects of cocaine in all circumstances. When cocaine is administered with a high dose, it
would be extremely difficult to have a sufficiently high amount of antibodies for binding
with all cocaine molecules. If antibodies could not completely suppress the cocaine
reward in the brain, it may induce patient using a higher dose to override the cocaine
vaccine effects. Another disadvantage is that there is so much variability in antibody
responses to cocaine among the human subjects. TA-CD, a cocaine vaccine made from
succinyl norcocaine conjugated to cholera toxin B, has finished three-phase clinical trials
in 2009. This vaccine showed no serious adverse effects and patients who achieved
sufficient antibody levels reduced their cocaine use. However, only 38% of the subjects
in the trial attained the ―high‖ amount of antibody (43 g/mL).(53-55) Report also
showed that antibody response of most subjects is 6 weeks later, and cannot last for
longer than 12 weeks.(55) Furthermore, for the active immunization, it takes quite a long
time to generate enough amounts of antibodies, which will limit its potential clinical use.
To improve the efficiency of vaccine, the better vaccine and adjuvant, and/or vaccination
strategies will be needed to produce a higher-titer and longer-lasting antibody in order to
fully block the effects of commonly used dose of cocaine.

1.4.2 Cocaine-metabolizing enzyme for treatment of cocaine abuse
Compared with the above-mentioned immunological strategy, developing a highly
efficient cocaine-metabolizing enzyme for treatment of cocaine abuse can be a more
promising direction.(17, 56-58) Enzyme therapy has the advantage of higher efficiency
over antibody and vaccine approaches. The desired therapeutic enzymes can not only
bind with cocaine but also metabolize it in the serum before it reaches CNS. What is
more, an enzyme molecule can free itself for further degradation of another cocaine
molecule. Thus, one enzyme molecule can keep metabolizing cocaine molecules as long
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as it retains its activity. Besides, it has potential advantages over active immunization
since its administration would immediately enhance cocaine metabolism and would not
require an immune response to be effective, which is important for patients with cocaine
overdose in ED.(17)
In order to find out the possible enzyme candidate, it is necessary to understand the
metabolism pathways of cocaine in human. Around 95% of cocaine is metabolized in
human by enzymatic hydrolysis of the two ester groups.(58, 59) Hydrolysis of cocaine at
the benzoyl ester generates ecgonine methyl ester (EME) and benzoic acid; whereas
hydrolysis of cocaine at the methyl ester produces benzoylecgonine (BE) and
methanol.(60) BChE is the primary cocaine hydrolase in human plasma capable of
hydrolyzing cocaine at the benzoyl ester.(61) One of the liver carboxylesterases, known
as hCE-1, is responsible for hydrolyzing cocaine at the methyl ester.(58, 62) The
remaining 5% is metabolized through oxidation by the liver microsomal cytochrome
P450 system, producing norcocaine.(58, 60) Among the metabolites of cocaine (EME,
BE, and norcocaine), EME is known to be the least pharmacologically active and may
even cause vasodilation (63), whereas both BE and norcocaine have similar physiological
effects as cocaine, and cause vasoconstriction and lower the seizure threshold.(58, 63-65)
Moreover, norcocaine is hepatotoxic due to the further oxidative metabolite of
norcocaine.(58, 66, 67) Therefore, the metabolic pathway through BChE-catalyzed
hydrolysis at the benzoyl ester is most promising for cocaine detoxification from the body.

12

Figure 1.2 Cocaine metabolic pathways in human.

Cocaine, as a stimulant on brain, can cross the blood-brain barrier back and forth
rapidly, and cocaine concentrations in the brain and plasma can quickly reach the
equilibrium as demonstrated in the positron emission tomography (PET) imaging
studies.(68, 69) Although exogenous enzymes administrated into the plasma do not enter
the brain, if cocaine in the plasma is quickly metabolized, cocaine in the brain will move
back to the plasma. Eventually, cocaine in CNS can be cleared by the exogenous enzyme
administrated into the plasma. Therefore, a cocaine-metabolizing enzyme can be used for
cocaine abuse treatment. For cocaine overdose treatment, it requires the enzyme to have a
high catalytic efficiency in order to rapidly clear cocaine from the body.
As mentioned earlier, a single dose of cocaine would cause change in gene
expression levels of dopamine transporter and receptor, which could persist for months
after withdrawal. That is the reason why cocaine addiction is so hard to treat and so easy
to relapse. For cocaine addiction treatment, it is necessary to completely block the
stimulant effects of cocaine for quite a long time, which requires the enzyme to have a
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high catalytic efficiency and long circulation time in the body. Under this condition, the
patient can have a better chance to bring the function of the brain’s communication
system back to normal.

1.5 Human BChE as a potential therapeutic enzyme for treatment of cocaine abuse
Human BChE has been recognized as a promising candidate for metabolizing
cocaine. BChE naturally exists in human body, mainly in plasma, liver, kidney, and lung.
It was first called pseudocholinesterase because of its ability to hydrolyze acetylcholine
(ACh). It has been known that complete inhibition of BChE activity has no effect on
muscle contraction.(70) So it is not BChE’s main function to hydrolyze ACh. Studies
have suggested that BChE is involved in neurodegenerative disorders such as Alzheimer's
disease (AD), and may be an important drug target for development of new treatments of
AD.(71, 72) The exact biological function of BChE is not completely clear yet.(60) It has
been proposed to be a housekeeping enzyme since it is responsible for detoxification of a
wide range of toxins including succinylcholine, organophosphates, and cocaine.(73-75)
Human BChE has exhibited several advantages in clinical use as a potential anticocaine medication.(17, 76) First, BChE is the primary enzyme to hydrolyze cocaine in
human body and produce biological inactive metabolites, and thus to help reducing the
reinforcing and toxic effects of cocaine. Many studies have demonstrated that
administration of exogenous human BChE (purified from donated blood) accelerates
cocaine metabolism and decreases cocaine’s half-life in rodents.(60) Second, human
BChE is from a human source, and there are over 65 different naturally occurring variants
of human BChE, and none of them is antigenic.(77, 78) So, the immune response, which
is usually evoked by exogenous protein, may be avoided. Third, human BChE has a long
history of clinical use to detoxify organophosphates, carbamate pesticide, and
succinylcholine without adverse effects observed.
However, the potential use of human BChE in cocaine detoxification is limited by
its low catalytic activity (kcat = 4.1 min-1 and KM = 4.5 µM) against (-)-cocaine (17, 79),
which is not sufficient to rapidly clear cocaine from the body. Both cocaine addiction and
overdose treatments require the enzyme to have a sufficiently high catalytic activity
against (-)-cocaine to quickly clear cocaine from body and prevent it from entering the
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brain. One interesting fact is that the activity of human BChE against the synthetic (+)cocaine (kcat = 6420 min-1 and KM = 4.7 µM) is ~1500-fold higher than that against (-)cocaine and (+)-cocaine is biological inactive (80), which may give us some insights in
re-engineering of human BChE for cocaine abuse treatment. It is reported that a very low
dose of 0.2 mg/kg (-)-cocaine has a half-life of 47 min, whereas (+)-cocaine at the same
dose can be cleared from body by BChE within seconds.(48) PET mapping (+)- and (-)cocaine binding in baboon indicates that (+)-cocaine has no uptake in CNS, whereas (-)cocaine peaks in minutes primarily at striatum.(68, 81) The main reason why (+)-cocaine
is biologically inactive could be that it is hydrolyzed so rapidly by BChE that it never
reached the CNS for PET imaging.(68, 81) If BChE can be re-engineered to obtain an
activity against (-)-cocaine as high as it against (+)-cocaine, it would be feasible for
treatment of cocaine addiction and overdose.

1.6 Further development of the therapeutic enzymes
Cocaine, recognized as one of the most reinforcing drugs of abuse, has caused
serious medical and social problems. Unfortunately, there is still no FDA-approved
effective treatment for cocaine addiction or overdose. Due to ineffectiveness and/or
unwanted side effects and/or its potential addiction tendency, no clinically useful
pharmacodynamic agent specific for cocaine abuse treatment has been identified yet.
However, enzyme therapy has been recognized as a promising approach to treat cocaine
abuse. As a good candidate for this purpose, human BChE has several therapeutic
potentials, but the application is limited by its low catalytic activity against (-)-cocaine.
Dr. Zhan’s lab has successfully designed and discovered a series of high-activity mutants
of human BChE, using novel integrated computational-experimental approach. One of
the BChE mutants designed in our group, i.e. A199S/S287G/A328W/Y332G BChE
(denoted as E14-3), fused with human serum albumin (denoted as AlbuBChE) is under
human clinical trial phase II by Teva Pharmaceutical Industries Ltd. When AlbuBChE
was administered to human subjects by intramuscular injection, no significant increase in
blood pressure was observed, nor was lethargy reported. The findings indicate that
intramuscular administration of AlbuBChE to humans at the specified dosages (50 to 300
mg per subject) did not result in any unacceptable side effects and that the specified
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dosages will allow for the successful treatment of cocaine exposure. Human subjects
administrated with AlbuBChE did not report a significant increase in cocaine craving. In
contrast, the desire to use cocaine again and the ―overall drug liking‖ are significantly
decreased following the AlbuBChE dosing.(82) Another promising BChE mutant
designed in our lab, i.e. A199S/F227A/S287G/A328W/Y332G BChE (denoted as E12-7)
which was known as the most active cocaine hydrolase reported, has a ~2000-fold
improved catalytic efficiency against (-)-cocaine compared to the wild-type BChE, a ~2fold improved catalytic efficiency against (-)-cocaine compared to E14-3.(76) The in
vivo data in a mice model demonstrated that the minimum effective dose of the enzyme
to protect mice from cocaine-induced lethality (180 mg/kg) is ~0.3 mg/kg.(76)
In summary, the rationally designed BChE mutants are valuable in development of
anti-cocaine therapeutic agents. This dissertation is mainly focused to address the
possible concerns in further development of the promising BChE mutants for cocaine
abuse treatment, such as whether the administration of this exogenous enzyme will affect
the cholinergic system, whether it can efficiently hydrolyze the cocaine’s toxic
metabolites, whether the commonly used therapeutic agents will significantly affect the
catalytic activity of E12-7 against cocaine when they are co-administered. In addition, an
effort to discover new mutants with further improved activity led to a more promising
therapeutic BChE mutant A199S/F227A/P285Q/S287G/A328W/Y332G (denoted as
E20-7). The identified mutants of human BChE are expected to be valuable candidates
for development of a more efficient enzyme therapy for cocaine abuse.
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Chapter Two: Substrate Selectivity of High-Activity Mutants of Human
Butyrylcholinesterase

Summary
Cocaine is one of the most addictive drugs, and there is still no FDA-approved
medication specific for cocaine. A promising therapeutic strategy is to accelerate cocaine
metabolism producing biologically inactive metabolites via a route similar to the primary
cocaine-metabolizing pathway, i.e. cocaine hydrolysis catalyzed by human BChE in
plasma. However, the native BChE has a low catalytic efficiency against the abused
cocaine, i.e. (-)-cocaine. Our recently designed and discovered mutant E12-7
(A199S/F227A/S287G/A328W/Y332G) and other mutants of human BChE have a
considerably improved catalytic efficiency against (-)-cocaine. For the investigation
described in this chapter, we carried out both computational modeling and experimental
kinetic analysis on the catalytic activities of these promising new BChE mutants against
other

known

substrates,

including

neurotransmitter

acetylcholine

(ACh),

acetylthiocholine (ATC), butyrylthiocholine (BTC), and (+)-cocaine, in comparison with
the corresponding catalytic activity against (-)-cocaine. Both the computational modeling
and kinetic analysis have consistently revealed that all of the examined amino-acid
mutations only considerably improve the catalytic efficiency of human BChE against (-)cocaine, without significantly improving the catalytic efficiency of the enzyme against
anyone of the other substrates examined. In particular, all of the examined BChE mutants
have an even slightly lower catalytic efficiency against neurotransmitter ACh compared
to the wild-type BChE. This observation gives us confidence in development of an anticocaine enzyme therapy by using one of these BChE mutants, particularly the E12-7
mutant. The studies described in this chapter have been published.(83)

2.1 Significance of substrate selectivity of the human BChE mutants
The integrated computational-experimental studies have led to discovery of a series
of BChE mutants with a significantly improved catalytic efficiency against (-)cocaine.(76, 84-89) The first one of our designed and discovered high-activity mutants of
human BChE, i.e. the A199S/S287G/A328W/Y332G mutant (84), was validated by an
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independent group of scientists who concluded that this mutant is ―a true CocH with a
catalytic efficiency that is 1,000-fold greater than wild-type BChE‖.(90, 91) This BChE
mutant is currently in double-blind, placebo-controlled clinical trials in humans by Teva
Pharmaceutical Industries Ltd for cocaine abuse treatment.(17) Our recently designed and
discovered new mutants (76, 89) of human BChE are even more active against (-)cocaine in vitro and in vivo, without knowing whether these mutations also considerably
increase the catalytic efficiencies against other substrates.
An ideal, therapeutically valuable mutant of human BChE should have not only a
high catalytic activity against (-)-cocaine, but also certain selectivity for (-)-cocaine over
neurotransmitter ACh, the only known natural substrate of BChE in the body, such that
one would not expect systemic administration of the BChE mutant to interrupt
cholinergic transmission. The catalytic activities of wild-type BChE against
neurotransmitter ACh, ATC, BTC, and (+)-cocaine are all much higher than that against
(-)-cocaine. So, we wanted to know whether the same amino-acid mutations designed to
considerably increase the catalytic activity of BChE against (-)-cocaine also considerably
increase the catalytic activities of BChE against other substrates. In this chapter, both
computational modeling and experimental kinetic analysis on the catalytic activities of
these promising new BChE mutants against (-)-cocaine and other known substrates were
performed, in order to evaluate the substrate selectivity of these designed high-activity
mutants of human BChE.

2.2 Computational methods
Various substrates interacting with human BChE and its mutants were modeled for
their enzyme-substrate binding complexes (denoted as ES’s) and transition states for the
initial reaction step (denoted as TS1’s) by using the same modeling strategy and approach
that we used to study (-)-cocaine interacting with the enzymes.(76, 84-89) The general
strategy of performing an energy minimization or molecular dynamics (MD) simulation
on a transition state structure of an enzymatic reaction using a classical force field
(molecular mechanics) has been described and justified in our recent reports.(76, 84, 88,
89, 92) During the energy minimization or MD simulation on the TS1 structure, the
lengths of transition bonds (i.e. the covalent bonds that are being broken or formed
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gradually during the initial reaction step) were restrained while all other geometric
parameters were allowed to move. The transition bond lengths used in our modeling of
the TS1 structures for each pair of enzyme and substrate were based on our previously
reported molecular modeling and reaction-coordinate calculations on BChE-catalyzed
hydrolysis of (-)-cocaine or ACh or ATC.(76, 88, 93) Specifically, the transition-bond
lengths used in our modeling of the TS1 structures with (−)-cocaine or (+)-cocaine were
the same as those in the QM/MM-optimized TS1 geometry for BChE-catalyzed
hydrolysis of (-)-cocaine.(78) The transition-bond lengths used in our modeling of the
TS1 structures with ACh were the same as those in the QM/MM optimized TS1 geometry
for BChE-catalyzed hydrolysis of Ach.(106) The transition-bond lengths used in our
modeling of the TS1 structures with ATC or BTC were the same as those in the
QM/MM-optimized TS1 geometry for BChE-catalyzed hydrolysis of ATC.(93) The
amino acid mutations and the minor structural difference in the substrate were not
expected to significantly change the transition-bond lengths based on our previous
experience in the transition-state simulations.(76, 84, 89, 92, 94, 95) As discussed in our
previous computational studies related to the transition-state modeling,(76, 84, 89, 92, 94,
95) the computational procedures for modeling a TS1 structure were the same as those
for modeling the corresponding ES structure, except for keeping the transition bond
lengths restrained during the energy minimization or MD simulation on the TS1 structure.
Technically, each transition-bond length in a TS1 structure was restrained by defining a
new type of covalent bond whose force constant was one half of the normal covalent
bond between the two atoms. It should be pointed out that the sole purpose of performing
this type of computational modeling on a transition state was to examine the hydrogen
bonding interaction between the carbonyl group of the substrate and the oxyanion hole of
the enzyme. We were only interested in the modeled structures, as the total energies
calculated in this way would be meaningless. The modeled structures were used to
estimate the hydrogen bonding energies (HBE) by using an HBE equation utilized in our
earlier studies.(84)
The initial structures of BChE and the mutants used in the molecular modeling were
prepared on the basis of our previous MD simulation on the enzyme-substrate complex
for wild-type BChE binding with (-)-cocaine.(84, 88, 96) Our previous MD simulations
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on the enzyme-substrate complexes started from the X-ray crystal structure deposited in
the Protein Data Bank (pdb code: 1P0P).(97) The general procedure for carrying out the
MD simulations on the enzyme-substrate interactions in water was essentially the same as
that used in our previously reported computational studies on other complexes. Each
starting structure was neutralized by adding counter ions (one chloride ion) and was
solvated in an orthorhombic box of TIP3P water molecules with a minimum solute-wall
distance of 10 Å (which means that the shortest distance between an atom of the
enzyme–substrate complex and the boundary of the box is longer than 10 Å). The
obtained box sizes of the solvated systems were about 99 Å × 92 Å × 87 Å. All the
energy minimizations and MD simulations (using Newton’s equations of motion) were
performed by using the Sander module of the Amber11 package.(98) The solvated
systems were carefully equilibrated and fully energy-minimized. First, the solvent
molecules were minimized for 5000 steps (including 2500 steps using the steepest
descent method and 2500 steps using the conjugate gradient method) with the ligand and
enzyme restrained. Second, the solvent, ligand, and side chains of the enzyme were
energy-minimized for 1000 steps (including 500 steps using the steepest descent method
and 500 steps using the conjugate gradient method) with the backbone of enzyme
restrained. Finally the whole system was energy-minimized for 5000 steps (including
2500 steps using the steepest descent method and 2500 steps using the conjugate gradient
method).These systems were gradually heated from T = 10 K to T = 298.15 K in 30 ps
before running the MD simulation at T = 298.15 K for 1 ns or longer, making sure that
we obtained a stable MD trajectory for each of the simulated structures. The time step
used for the MD simulations was 2 fs. Periodic boundary conditions in the NPT ensemble
at T = 298.15 K with Berendsen temperature coupling and P = 1 atm with isotropic
molecule-based scaling were applied. The SHAKE algorithm was used to fix all covalent
bonds containing hydrogen atoms. The non-bonded pair list was updated every 10 steps.
The particle mesh Ewald (PME) method was used to treat long-range electrostatic
interactions. A residue-based cutoff of 10 Å was utilized to the non-covalent interactions.
The final snapshot of the stable MD trajectory was fully energy-minimized using the
steepest descent method for 5000 steps and then the conjugate gradient method until the
convergence criterion for an energy gradient of 0.1 kcal mol−1 Å−1 was achieved.
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2.3 Experimental methods
2.3.1 Enzyme expression
Both wild-type and mutants of human BChE were expressed and their enzyme
activities against various substrates were assayed at the same time under the same
experimental conditions; the wild-type was used a standard reference and validated
according to the catalytic parameters reported for the wild-type in literature. The proteins
(wild-type and mutants of BChE) were expressed in human embryonic kidney 293F cells.
Cells at the density of ~1 × 106 cells/ml were transfected by 293fectin reagent-DNA
complexes at the ratio of 2 μl : 1 μg per ml of the cells. Cells were cultured for five more
days. The culture medium was harvested for the BChE activity assays.

2.3.2 Kinetic activity of human BChE and its mutants against different substrates
For determining the catalytic activity of the enzymes against (-)-cocaine, we used a
sensitive radiometric assay based on toluene extraction of [3H](-)-cocaine labeled on its
benzene ring.(99) In brief, to initiate the enzymatic reaction, 100 nCi of [3H](-)-cocaine
along with (-)-cocaine was mixed with culture medium. The enzymatic reactions
proceeded at room temperature (25oC) with varying concentrations of (-)-cocaine. The
reactions were stopped by adding 200 l of 0.1 M HCl, which neutralized the liberated
benzoic acid while ensuring a positive charge on the residual (-)-cocaine. [3H]benzoic
acid (a product of (-)-cocaine hydrolysis) was extracted by 1 ml of toluene and measured
by scintillation counting. Finally, the measured (-)-cocaine concentration-dependent
radiometric data were analyzed by using the standard Michaelis-Menten kinetics so that
the catalytic parameters were determined along with the use of a well-established
standard enzyme-linked immunosorbent assay (ELISA) protocol.(84) The enzyme
activity assay with [3H]ACh was similar to the assay with [3H](-)-cocaine. The primary
difference is that the enzymatic reaction was stopped by addition of 200 µl of 0.2 M HCl
containing 2 M NaCl and that the product was [3H]acetic acid for the ACh hydrolysis. All
measurements were performed at room temperature.
The catalytic activities of the enzymes against ATC, BTC, and (+)-cocaine were
determined by UV-Vis spectrophotometric assays using a GENios Pro Microplate Reader
(TECAN, Research Triangle Park, NC) with the XFluor software. (+)-Cocaine were
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dissolved in water to make a 0.1 M stock containing 34 mg/ml. Aliquots were frozen at 20°C, thawed once, and discarded. The reaction rate of (+)-cocaine hydrolysis was
measured at 25°C by recording the time-dependent absorption at 230 nm. ATC and BTC
stock solutions of 0.2 M were prepared in water and frozen at -20°C. The reaction rates
were measured at 25°C by recording the time-dependent absorption at 450 nm in the
presence of 1 mM dithiobisnitrobenzoic acid, in 0.1 M potassium phosphate, pH 7.2.

2.4 Insights from molecular modeling
2.4.1 The interaction of (-)-cocaine with human BChE and its mutants
Molecular modeling enabled us to understand how human BChE and its mutants
interact with ACh, ATC, BTC, (+)-cocaine, and (-)-cocaine in the ES and TS1 structures.
According to the modeling, for (-)-cocaine interacting with wild-type BChE, there is only
one hydrogen bond (H-bond) between the carbonyl oxygen of (-)-cocaine and the
oxyanion hole (G116, G117, and A199) in the ES structure, and there are two H-bonds in
the

TS1

structure,

as

seen

in

Figure

2.1A

and

2.1B.

With

the

A199S/F227A/S287G/A328W/Y332G mutant (E12-7), there are two H-bonds between
the carbonyl oxygen of (-)-cocaine and the oxyanion hole (G116, G117, and S199) in the
ES structure and three H-bonds in the TS1 structure, as seen in Figure 2.1C and 2.1D.
The extra H-bond in both the ES and TS1 structures is with the hydroxyl group of S199
after the A199S mutation. The modeled ES and TS1 structures suggest that this mutant
should have a significantly higher catalytic activity against (-)-cocaine compared to the
wild-type BChE.
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Figure 2.1 The energy-minimized ES and TS1 structures for (-)-cocaine interacting with
wild-type human BChE and E12-7.

For

(-)-cocaine

A199S/A328W/Y332G

interacting

with

(E14-1),

A199S/S287G/A328W/Y332G

(E14-3),

other

mutants

examined,

A199S/F227A/A328W/Y332G
and

i.e.

the

(E14-2),

A199S/F227A/S287G/A328W/E441D

(E12-4) mutants, the modeled ES and TS1 structures are all qualitatively similar to the
corresponding ES and TS1 structures with the E12-7 in terms of the number of H-bonds.
Thus, we only depict the ES and TS1 structures with the E12-7 in Figure 2.1 as a typical
example of the five mutants examined. The modeled ES and TS1 structures qualitatively
suggest that each of these mutants should have a considerably higher catalytic activity
against (-)-cocaine compared to the wild-type BChE.
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2.4.2 The interaction of other substrates with human BChE and its mutants
For other substrates (including ACh, ATC, BTC, and (+)-cocaine) interacting with
the wild-type BChE or anyone of the aforementioned mutants, there are always two Hbonds between the carbonyl oxygen of the substrate and the oxyanion hole (G116, G117,
and A/S199) in the ES structure and three H-bonds in the TS1 structure. Depicted in
Figures 2.2 to 2.5 are the modeled ES and TS1 structures with wild-type BChE and a
representative mutant E12-7. The hydroxyl group of S199 in the mutant does not form an
extra H-bond in the ES or TS1 structure for the mutant interacting with any substrate
other than (-)-cocaine, suggesting that these BChE mutants should not have dramatically
improved catalytic activities against ACh, ATC, BTC, and (+)-cocaine compared to the
wild-type BChE.
Based on the modeling results, the computationally examined five sets of mutations
are all expected to considerably improve the catalytic efficiency of human BChE against
(-)-cocaine, without considerably improving the catalytic efficiency of human BChE
against ACh, ATC, BTC, or (+)-cocaine.
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Figure 2.2 The energy-minimized ES and TS1 structures for (+)-cocaine interacting with
wild-type human BChE and E12-7.
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Figure 2.3 The energy-minimized ES and TS1 structures for ACh interacting with wildtype human BChE and E12-7.
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Figure 2.4 The energy-minimized ES and TS1 structures for ATC interacting with wildtype human BChE and E12-7.
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Figure 2.5 The energy-minimized ES and TS1 structures for BTC interacting with wildtype human BChE and E12-7.

2.5 Kinetic parameters
Based on the computational insights, we carried out in vitro experimental tests,
including

the

protein

A199S/A328W/Y332G

expression
(E14-1),

and

enzyme

activity

assays,

A199S/F227A/A328W/Y332G

on

the

(E14-2),

A199S/S287G/A328W/Y332G (E14-3), A199S/F227A/S287G/A328W/E441D (E12-4),
and A199S/F227A/S287G/A328W/Y332G (E12-7) mutants. To minimize the possible
systematic experimental errors of the kinetic data, we also expressed the wild-type
enzyme and performed the kinetic analysis along with the mutants under the same
experimental conditions, and compared the catalytic efficiencies of the mutants to the
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corresponding catalytic efficiencies of the wild-type enzyme against various substrates.
Depicted in Figures 2.6 to 2.10 are the measured kinetic data. Summarized in Table 1 are
the determined kinetic parameters.
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Figure 2.6 Kinetic data for (-)-cocaine hydrolysis catalyzed by wild-type human BChE
and various BChE mutants.
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Figure 2.7 Kinetic data for (+)-cocaine hydrolysis catalyzed by wild-type human BChE
and various BChE mutants.
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Figure 2.8 Kinetic data for ACh hydrolysis catalyzed by wild-type human BChE and
various BChE mutants.
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Figure 2.9 Kinetic data for ATC hydrolysis catalyzed by wild-type human BChE and
various BChE mutants.
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Figure 2.10 Kinetic data for BTC hydrolysis catalyzed by wild-type human BChE and
various BChE mutants.
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Table 2.1 Kinetic parameters determined for (-)-cocaine, (+)-cocaine, ACh, ATC, and
BTC hydrolyses catalyzed by wild-type BChE and its mutants.
Substrate

KM

Enzyme a

kcat
-1

kcat/KM
-1

-1

RCEb

(µM)

(min )

(M min )

wild-type BChEc

4.5

4.1

9.1 × 105

1

A199S/A328W/Y332G

5.1

560

1.1 × 108

121

A199S/F227A/A328W/Y332G

4.4

1560

3.6 × 108

396

A199S/S287G/A328W/Y332G

3.1

3,060

9.9 × 108

1,080

A199S/F227A/S287G/A328W/E441D

1.1

1,730

1.6 × 109

1,730

A199S/F227A/S287G/A328W/Y332G

3.1

5,700

1.8 × 109

2,020

wild-type BChE

4.7

6,420

1.4 × 109

1

A199S/A328W/Y332G

5.0

2,820

5.6 × 108

0.40

A199S/F227A/A328W/Y332G

4.4

6,060

1.4 × 109

1.01

A199S/S287G/A328W/Y332G

6.3

5,620

8.9 × 108

0.65

A199S/F227A/S287G/A328W/E441D

4.7

10,800

2.3 × 109

1.68

A199S/F227A/S287G/A328W/Y332G

4.6

8,990

2.0 × 109

1.43

wild-type BChEd

148

61,200

4.1 × 108

1

A199S/A328W/Y332G

156

4,190

2.7 × 107

0.066

A199S/F227A/A328W/Y332G

189

7,430

3.9 × 107

0.095

A199S/S287G/A328W/Y332G

36

5,320

1.5 × 108

0.37

A199S/F227A/S287G/A328W/E441D

27

10,400

3.9 × 108

0.95

A199S/F227A/S287G/A328W/Y332G

37

11,900

3.2 × 108

0.78

(-)-cocaine

(+)-cocaine

ACh
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Table 2.1 (continued)
wild-type BChEe
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20,200

6.1 × 108

1

A199S/A328W/Y332G

31

3,410

1.1 × 108

0.18

A199S/F227A/A328W/Y332G

41

6,870

1.6 × 108

0.26

A199S/S287G/A328W/Y332G

21

7,880

3.7 × 108

0.60

A199S/F227A/S287G/A328W/E441D

12

14,000

1.2 × 109

1.99

A199S/F227A/S287G/A328W/Y332G

20

14,800

7.2 × 108

1.19

wild-type BChEf

17

29,500

1.7 × 109

1

A199S/A328W/Y332G

8.9

6,100

6.8 × 108

0.39

A199S/F227A/A328W/Y332G

11

74,700

6.8 × 109

3.91

A199S/S287G/A328W/Y332G

5.3

14,400

2.7 × 109

1.57

A199S/F227A/S287G/A328W/E441D

8.9

17,800

2.0 × 109

1.15

A199S/F227A/S287G/A328W/Y332G

13

28,000

2.2 × 109

1.24

ATC

BTC

a

Unless indicated otherwise, all kinetic parameters listed in this table were determined in
the present study.
b
RCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM value
of the mutant to that of wild-type BChE against the same substrate.
c
Data for wild-type BChE from reference.(79)
d
The kcat value for wild-type BChE was reported in reference.(100)
e
The kcat value for wild-type BChE from reference.(101)
f
The kcat value for wild-type BChE was reported in reference.(101)
Based on the kinetic parameters summarized in Table 2.1, all of the five BChE
mutants examined in this study have a considerably improved catalytic efficiency (kcat/KM)
against (-)-cocaine, with the improvement ranging from 121 to 2020-fold. The same
mutations do not dramatically improve the catalytic efficiencies of human BChE against
the other substrates. Within the five mutants examined, the values of the relative catalytic
efficiency (RCE), i.e. the ratio of the catalytic efficiency of the mutant to that of the wildtype BChE, range from 0.4 to 1.68 for (+)-cocaine, 0.066 to 0.95 for ACh, 0.18 to 1.99
for ATC, and 0.39 to 3.91 for BTC. The largest RCE value is associated with the
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A199S/F227A/S287G/A328W/E441D mutant for both (+)-cocaine (1.68-fold) and ATC
(1.99-fold), and the A199S/F227A/A328W/Y332G mutant for BTC (3.91-fold).
For ACh (which is the only known endogenous substrate of BChE in the body), all
of the BChE mutants actually have a slightly lower catalytic efficiency compared to the
wild-type BChE. So, all of these mutants only have a considerably improved catalytic
efficiency against (-)-cocaine without any improvement on the catalytic efficiency of
BChE against ACh. As a result, the catalytic efficiencies of these BChE mutants against
(-)-cocaine are all higher than the corresponding catalytic efficiencies against ACh, as
seen in Table 2.1.
The observed substrate selectivity of these mutants may be used to address a
potential question concerning whether the enzyme therapy using a high-activity mutant of
human BChE would significantly affect the cholinergic transmission and, thus, produce
adverse effects. In fact, previous studies evaluating wide-type human BChE as a
prophylaxis against chemical warfare nerve agents found no autonomic or motor
impairment in rats, guinea pigs, or primates, even with the high doses raising the plasma
enzyme levels for 50 to 100-fold.(102-107) This is not surprising due to several factors.
First, the molar concentrations of acetylcholinesterase (AChE) and BChE in blood are
roughly similar (108) and BChE has a lower catalytic efficiency against ACh compared
to AChE. Second, cholinergic synapses in the brain are insulated from plasma enzymes
by the blood-brain barrier and, thus, the exogenous enzymes in plasma would not reach
the brain. In addition, peripheral cholinergic synapses are densely packed with AChE. It
has been known that mouse neuromuscular junction has 5 × 1019 catalytic AChE subunits
per cc, i.e. ~0.1 mM (109), whereas mouse plasma BChE levels are below 0.1 μM (108).
For these reasons, even high levels of plasma BChE activity are unlikely to affect motor
transmission. The current observation that none of these high-activity mutants of human
BChE has an improved catalytic efficiency against ACh compared to the wild-type BChE
gives us additional confidence in development of an enzyme therapy by using one of
these BChE mutants, particularly the A199S/F227A/S287G/A328W/Y332G mutant with
the highest catalytic efficiency against (-)-cocaine.
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2.6 Conclusion
Both the computational modeling and experimental kinetic analysis have
consistently revealed that all of the five BChE mutants examined in this study only have
a considerably improved catalytic efficiency against (-)-cocaine, without dramatically
improving the catalytic efficiency against any of the other substrates examined compared
to the wild-type BChE. In particular, all of these BChE mutants have an even slightly
lower catalytic efficiency against ACh compared to the wild-type BChE. The observation
of the substrate selectivity gives us additional confidence in development of an enzyme
therapy

by

using

one

of

these

BChE

mutants,

particularly

the

A199S/F227A/S287G/A328W/Y332G mutant (E12-7) with the highest catalytic
efficiency against (-)-cocaine.
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Chapter Three: Kinetic Characterization of Human Butyrylcholinesterase Mutants
for Hydrolysis of Cocaethylene

Summary
It is known that majority of cocaine users also consume alcohol. Alcohol can react
with cocaine to produce a significantly more cytotoxic compound, cocaethylene. Hence, a
truly valuable cocaine-metabolizing enzyme for cocaine abuse/overdose treatment should
be efficient for not only cocaine itself, but also cocaethylene. The catalytic parameters
(kcat and KM) of human BChE and two mutants (E14-3 and E12-7) for cocaethylene have
been characterized in this chapter, for the first time, in comparison with those for cocaine.
Based on the obtained kinetic data, wild-type human BChE has a lower catalytic activity
for cocaethylene (kcat = 3.3 min-1, KM = 7.5 M, and kcat/KM = 4.40 × 105 M-1 min-1)
compared to its catalytic activity for (-)-cocaine. E14-3 and E12-7 have a considerably
improved catalytic activity against cocaethylene compared to the wild-type BChE. E12-7
is identified as the most efficient enzyme for hydrolyzing cocaethylene in addition to its
high activity for (-)-cocaine. E12-7 has an 861-fold improved catalytic efficiency for
cocaethylene (kcat = 3600 min-1, KM = 9.5 M, and kcat/KM = 3.79 × 108 M-1 min-1). It has
been demonstrated that E12-7 as an exogenous enzyme can indeed rapidly metabolize
cocaethylene in rats. Further kinetic modeling has suggested that E12-7 with an identical
concentration as that of the endogenous BChE in human plasma can effectively eliminate
(-)-cocaine, cocaethylene, and norcocaine in simplified kinetic models of cocaine abuse
and overdose associated with the concurrent use of cocaine and alcohol. The studies
described in this chapter have been published.(110)

3.1 Overview of possible treatment of combined cocaine-alcohol abuse using highactivity mutants
In humans, cocaine is metabolized through hydrolysis catalyzed by plasma enzyme
BChE that catalyzes hydrolysis at the benzoyl ester group (Figure 3.1), hydrolysis by two
liver carboxylesterases (hCE-1 and hCE-2) that catalyze hydrolysis at the methyl ester
and the benzoyl ester, respectively, and oxidation by liver microsomal cytochrome P450
(CYP) 3A4 to produce norcocaine which has similar physiological effects as of
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cocaine.(60, 111) BChE-catalyzed hydrolysis of cocaine at the benzoyl ester is the
primary cocaine-metabolizing pathway which is most suitable for amplification.
Unfortunately, wild-type BChE has a low catalytic efficiency against naturally occurring
(-)-cocaine (kcat = 4.1 min-1 and KM = 4.5 M).(74, 79, 96, 112, 113)

Figure 3.1 Cocaine metabolites produced in humans through hydrolysis by BChE,
oxidation by cytochrome P450 (CYP) 3A4, and reaction of cocaine with alcohol
(catalyzed by liver hCE-1).

As an additional challenge to cocaine abuse treatment, statistical data report that the
majority of cocaine users (e.g. 92% as of August 2013) (114) also consume alcohol
(which always refers to ethanol in this report). Alcohol can react with cocaine under hCE1 catalysis to produce a significantly more cytotoxic compound, cocaethylene, through
transesterification. With alcohol co-administration, ~24% (intravenous), ~34% (oral), or
~18% (smoked) of cocaine is converted to cocaethylene through transesterification.(115)
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Hence, a truly valuable mutant of human BChE for anti-cocaine enzyme therapy
development should be efficient for not only cocaine, but also norcocaine and
cocaethylene.
Our computationally designed mutations of human BChE have led to at least 1000fold improved catalytic efficiency against (-)-cocaine (76, 84-89) and norcocaine (116).
The first one of our designed high-activity mutants of human BChE, i.e. the
A199S/S287G/A328W/Y332G mutant (84), has been recognized as a true cocaine
hydrolase

(CocH)

suitable

for

testing

in

humans.(90,

91)

The

A199S/S287G/A328W/Y332G mutant is currently in double-blind, placebo-controlled
clinical trials in humans by Teva Pharmaceutical Industries Ltd for cocaine abuse
treatment.(17) Our more recently designed new mutants (76, 89) of human BChE are
even more effective against (-)-cocaine. However, it has been unknown whether any of
these mutants can also catalyze the hydrolysis of cocaethylene. To our best knowledge,
we have not seen a report on the kinetic parameters for cocaethylene hydrolysis catalyzed
by wild-type human BChE or any of these BChE mutants. What has been known in
literature is that cocaethylene produces more euphoria and possesses a longer half-life
than that of cocaine.(115, 117-120)
One might reasonably expect that the BChE mutants with a considerably improved
catalytic efficiency against cocaine should also have a considerably improved catalytic
efficiency against cocaethylene. However, the recently reported kinetic analysis of the
BChE mutants against acetylcholine (ACh), the only known natural substrate of BChE in
the body, revealed that the mutations did not improve the catalytic efficiency of BChE
against ACh.(83, 88) In fact, the catalytic efficiency of the examined BChE mutants
against ACh is slightly lower than that of the wild-type BChE. So, it is unknown whether
any of the BChE mutants reported so far has a significantly improved catalytic efficiency
against cocaethylene compared to the wild-type BChE.
In the present study, we have characterized the catalytic activity of wild-type human
BChE and our discovered A199S/S287G/A328W/Y332G mutant (denoted as E14-3 for
convenience) and A199S/F227A/S287G/A328W/Y332G mutant (denoted as E12-7 for
convenience) of human BChE against cocaethylene, in comparison with the
corresponding catalytic activities against (-)-cocaine and norcocaine. The obtained kinetic
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data have demonstrated that the BChE mutants examined in this study have not only a
considerably improved catalytic efficiency against (-)-cocaine and norcocaine, but also a
considerably improved catalytic efficiency against cocaethylene in vitro and in vivo
compared to the wild-type BChE. Further kinetic modeling has demonstrated that these
BChE mutants can effectively hydrolyze (-)-cocaine, cocaethylene and norcocaine at the
same time in simplified kinetic models of combined cocaine-alcohol abuse.

3.2 Materials and methods
3.2.1 Molecular modeling
Cocaethylene binding with human BChE and mutants was modeled by using our
previously simulated structures of the same enzymes.(43, 76, 84-87, 89) Our previous
molecular

dynamics

(MD)

simulations(88)

on

the

structures

of

enzyme-

cocaine/norcocaine complexes (116) started from the X-ray crystal structure deposited in
the Protein Data Bank (pdb code: 1P0P). For each enzyme (human BChE or mutant),
cocaethylene was docked into the possible active site of the enzyme by using the
AutoDock 4.2 program (121), as we previously did for the enzyme binding with (-)cocaine and norcocaine.(116) During the docking process, the Solis and Wets local
search method (122) was used for the conformational search and the Lamarkian genetic
algorithm (LGA) (121) was employed to deal with the enzyme-ligand interactions. The
grid size was set to be 120  120  120. The finally obtained enzyme-cocaethylene
binding structures were the ones with the lowest binding free energies.

3.2.2 Enzyme preparation and in vitro activity assays
Both wild-type and mutants of human BChE were expressed and their enzyme
activities against cocaethylene and (-)-cocaine were assayed at the same time under the
same experimental conditions so that the activity against cocaethylene can be compared
with that against (-)-cocaine for each enzyme. For the purpose of in vitro activity assays,
the proteins (wild-type human BChE and mutants) were expressed in human embryonic
kidney (HEK) 293F cells. Cells at the density of ~1 × 106 cells/ml were transfected by
293fectin reagent-DNA complexes at the ratio of 2 μl : 1 μg per ml of the cells. Cells
were cultured for five more days. The culture medium was harvested, and the protein was
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purified by using a two-step purification procedure (ion exchange chromatography
followed by affinity chromatography), as described previously in detail.(116) The
purified protein was dialyzed against phosphate-buffered saline and stored at 4°C or 80°C.
The catalytic activities of the enzymes against cocaethylene and (-)-cocaine were
determined by performing a UV-Vis spectrophotometric assay. Using the UV-Vis
spectrophotometric assay, the catalytic activities of the enzymes against cocaethylene and
(-)-cocaine were determined at the same time under the same experimental conditions.
The enzymatic reaction was initiated by adding 180 l of a substrate (cocaethylene or (-)cocaine) solution to 20 l of an enzyme solution. The final initial cocaethylene/(-)cocaine concentrations were as follows: 100, 50, 20, 10, 5, 2, and 1 M. The reaction
temperature was 25°C, and the buffer used was 0.1 M potassium phosphate (pH 7.4). The
initial rates of the enzymatic hydrolysis of cocaethylene/(-)-cocaine in various initial
substrate concentrations were estimated by following the change in the intrinsic
absorbance peak of cocaethylene/(-)-cocaine at 230 nm (see below for the UV-Vis
absorption spectra) with time using a GENios Pro Microplate Reader (TECAN, Research
Triangle Park, NC) with the XFluor software. The initial reaction rates were estimated
from the linear portions of the progress curves. All assays were carried out in triplicate.
The Michaelis-Menten kinetic analysis was performed by using Prism 5 (GraphPad
Software Inc., San Diego, CA) to determine the Vmax and KM values.

3.2.3 Subjects for in vivo studies
Male Sprague-Darley rats (200-250 g) were ordered from Harlan (Harlan,
Indianapolis, IN) and were housed initially in 2 to 4 rats per cage. All rats were allowed
ad libitum access to food and water and were maintained on a 12-hour light and dark
cycle with lights on at 8 AM in a room kept at a temperature of 21 to 22°C. Each rat was
used only once. Experiments were performed in a same colony room in accordance with
the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by
the National Institutes of Health. The animal protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Kentucky.
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3.2.4 Characterization of cocaethylene clearance accelerated by E12-7
Cocaethylene (formulated in the salt form of cocaethylene fumarate) was provided
by the National Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD),
and the E12-7 material used for in vivo studies in rats were prepared in our recently
reported study (123) developing and using stable CHO-S cells. Our in vitro assays
revealed that E12-7 expressed in the CHO-S cells had the same catalytic activities of that
expressed in HEK 293F cells. General anesthetic isoflurane was utilized with nose cone
during the administration of cocaethylene and E12-7 (or saline). Rats were injected with
saline or 0.15 mg/kg of E12-7 through the tail vein 1 min before i.v. injection of 3 mg/kg
cocaethylene (~7 μmol/kg). Four rats were used for each set of experiments (n=4), About
50 to 75 μl of blood from saphenous veins was collected into capillary tubes and
immediately diluted in 100 μl of 250 μM paraoxon at 2, 5, 15, 30, 60, 90, 120, 150, and
180 min after the i.v. injection of cocaethylene. Paraoxon is an irreversible BChE
inhibitor that can stop the enzymatic hydrolysis of cocaethylene between sampling and
analysis. The diluted blood samples were stored at -70°C and assayed using a HighPerformance Liquid Chromatographic (HPLC) method.
Benzoic acid is the product of cocaethylene hydrolysis catalyzed by the enzyme
(wild-type BChE or E12-7). The standard benzoic acid for the HPLC analysis was
purchased through Sigma Aldrich (Sigma Aldrich, St. Louis, MO). To assay the
cocaethylene and benzoic acid concentrations in the blood samples, the frozen whole
blood samples were thawed on ice for 3 hours. Then 150 μl of mobile phase (26%
acetonitrile and 74% water containing 0.1% TFA) was mixed with each sample, and 50
μl of 10% HClO4 was added to break the blood cell membrane. The mixture was
vortexed for 1 min and then centrifuged at 25,000 g for 15 min, and the supernatant was
transferred to an autosampler vial of which 200 μl was injected into the chromatographic
system. Chromatography was performed using a Waters 1525 binary HPLC pump
(Waters Corporation, Milford, MA), a Waters 2487 dual λ absorbance detector, a Waters
2475 multi λ fluorescence detector, and a Waters 717 plus autosampler. The flow rate
was 1 ml/min. The eluent was monitored at 230 nm for absorbance of benzoic acid and at
315 nm for fluorescence of cocaethylene while exciting at 230 nm. The cocaethylene
peaks appeared at 11.6 min, and the benzoic acid peaks occurred at 12.7 min. The
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concentrations of cocaethylene and benzoic acid were determined by comparing the
corresponding HPLC peak areas with those of authentic standards.

3.2.5 Kinetic modeling
Kinetic modeling of (-)-cocaine in humans was performed by use of a MatLab
program (developed in house) (116, 124, 125) in a way similar to that of our recently
developed pharmacokinetic modeling of (-)-cocaine in the presence of a cocainemetabolizing enzyme.(82, 116) The previously used kinetic models did not involve
cocaethylene. By using a one-compartment model, the present kinetic modeling also
accounted for the transformation of (-)-cocaine to cocaethylene and the subsequent
cocaethylene hydrolysis in the presence of a cocaine-metabolizing enzyme. Given in
Figure 3.2 are the reaction scheme and kinetic equations used in the present study. In the
kinetic model depicted in Figure 3.2, the function of alcohol in the transesterification is
similar to a co-factor of hCE-1, and the kinetic modeling is based on the assumption that
the alcohol concentration is high enough to reach the saturation in which the reaction rate
no longer can increase with further increasing the alcohol concentration.

Figure 3.2 Reaction scheme and kinetic equations used in the kinetic modeling. X(t) is the
concentration of X at time t (X = A to G). Vmax = kcat[E] (for cocaine hydrolysis), V´max =
k´cat[E] (for cocaethylene hydrolysis), and V˝max = k˝cat[E] (for norcocaine hydrolysis) in
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which [E] is the concentration of the enzyme (CocH) hydrolyzing all of the three
substrates (cocaine, cocaethylene and norcocaine). F1 and k1 represent the kinetic
parameters for the transesterification reaction of cocaine with alcohol (catalyzed by hCE1) to produce cocaethylene when the alcohol concentration is high enough to reach the
saturation; in this reaction, the function of alcohol is similar to that of a co-factor. F2 and
k2 refer to the kinetic parameters for cocaine oxidation (catalyzed by cytochrome P450
3A4) to norcocaine. V´max, V˝max, K´M, and K˝M values used in the modeling were based on
the reported overall enzyme activities (126) and the enzyme distributions in the
body.(127)

3.3 Insights from molecular docking
Molecular docking enabled us to understand how cocaethylene may bind with
human BChE and the mutants in comparison with (-)-cocaine binding with the same
enzymes. As seen in Figure 3.1, the only structural difference between cocaethylene and
(-)-cocaine is that the methyl group on the methyl ester of (-)-cocaine is replaced by an
ethyl group in cocaethylene. According to the enzyme-substrate binding structures
obtained from molecular docking, the binding mode for each enzyme (wild-type human
BChE or its mutant) with cocaethylene is essentially the same as that with (-)-cocaine,
particularly for the crucial interactions between the carbonyl oxygen of the substrate and
the oxyanion hole (consisting of residues #116, #117, and #199) of the enzyme. The
minor structural difference between cocaethylene and (-)-cocaine does not significantly
change the binding mode with the BChE or mutant. In particular, there is always only one
hydrogen bond between the carbonyl oxygen of the substrate and the oxyanion hole
(G117 backbone) of wild-type BChE no matter whether the substrate is cocaethylene or
(-)-cocaine, and there are always two hydrogen bonds between the carbonyl oxygen of
the substrate and the oxyanion hole (G117 backbone and S199 side chain) of the mutant
no matter whether the substrate is cocaethylene or (-)-cocaine. Depicted in Figure 3.3 are
the obtained enzyme-substrate binding structures for cocaethylene and (-)-cocaine with
wild-type human BChE and a representative mutant (E12-7). The binding structures with
E14-3 (not shown) are similar to those with E12-7 in terms of the overall hydrogen
bonding with the oxyanion hole.
45

The docking structures depicted in Figure 3.3 indicate that, regardless of whether the
substrate is cocaethylene or (-)-cocaine, the hydroxyl group of S199 side chain in the
mutant forms an additional, strong hydrogen bond with the substrate compared to that in
the wild-type BChE. Based on this common feature, the same amino-acid mutations that
can significantly improve the catalytic efficiency of human BChE against (-)-cocaine
may be expected to significantly improve the catalytic efficiency of the enzyme against
cocaethylene. Hence, the BChE mutants concerned in the present study are expected to
have a significantly improved catalytic efficiency against cocaethylene, although it has
been known that these BChE mutants do not have an improved catalytic efficiency
against ACh.(88)
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Figure 3.3 Docked structures of the wild-type BChE and E12-7 binding with
cocaethylene and (-)-cocaine: (A) Wild-type human BChE binding with (-)-cocaine; (B)
Wild-type human BChE binding with cocaethylene; (C) E12-7 binding with (-)-cocaine;
(D) E12-7 binding with cocaethylene. Indicated in the figure are the key distances (in Å)
of the carbonyl oxygen of the substrate with the hydrogen atoms of the oxyanion hole.

3.4 Kinetic parameters
In light of the computational insights, we carried out in vitro experimental tests,
including the protein expression and enzyme activity assays, on wild-type human BChE,
E14-3, and E12-7. The in vitro assays were based on our observation (Figure 3.4) that
cocaethylene also had an UV-Vis absorption peak at 230 nm as (-)-cocaine, and that the
absorption at 230 nm is linearly proportional to the concentration of cocaethylene or (-)cocaine. The in vitro assays enabled us to determine the catalytic activity of the enzymes
against cocaethylene in comparison with the corresponding activity against (-)-cocaine.
To minimize the possible systematic experimental errors of the kinetic data, for each
enzyme the catalytic activities against both cocaethylene and (-)-cocaine were assayed at
the same time under the same experimental conditions so as to reliably determine the
catalytic activity of the enzyme against cocaethylene relative to the known activity
against (-)-cocaine. Depicted in Figure 3.5 are the measured kinetic data. Summarized in
Table 1 are the kinetic parameters of the enzymes against cocaethylene in comparison
with those against (-)-cocaine and norcocaine.
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Figure 3.4 UV–visible absorptions of the enzyme and substrates. (A) UV-Vis absorption
of (-)-cocaine, cocaethylene, and E12-7. (B) Plot of the absorption at 230 nm versus the
concentration of (-)-cocaine. (C) Plot of the absorption at 230 nm versus the
concentration of cocaethylene.
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Figure 3.5 Kinetic data obtained in vitro for enzymatic hydrolysis of (-)-cocaine and
cocaethylene: (A) wild-type human BChE; (B) E14-3; (C) E12-7. To minimize the
possible systematic experimental errors of the kinetic data, each enzyme’s catalytic
activities against both cocaethylene and (-)-cocaine were assayed at the same time under
the same experimental conditions so as to reliably determine the kinetic parameters of the
enzyme against cocaethylene relative to those against (-)-cocaine. The reaction rate
(represented in M min-1 per nM enzyme) was determined by measuring the rate of the
change of the absorbance at 230 nm.

A survey of the kinetic parameters summarized in Table 1 reveals that both E14-3
and E12-7 examined in this study have a considerably improved catalytic efficiency
(kcat/KM) against cocaethylene. Wild-type BChE has a slightly lower catalytic activity
against cocaethylene (kcat = 3.3 min-1, KM = 7.5 M, and kcat/KM = 4.40 × 105 M-1 min-1)
compared to its catalytic activity against (-)-cocaine (kcat = 4.1 min-1, KM = 4.5 M, and
kcat/KM = 9.11 × 105 M-1 min-1). According to the kinetic parameters summarized in Table
1, E14-3 and E12-7 indeed have a significantly improved catalytic efficiency against
cocaethylene compared to the wild-type BChE: 517-fold for E14-3 and 861-fold for E127. In comparison with the catalytic activities of the same mutant for different substrates,
for both E14-3 and E12-7, the catalytic efficiency of the enzyme for cocaethylene is
lower than that for (-)-cocaine, but higher than that for norcocaine. Within the enzymes
examined in this study, the most efficient BChE mutant (E12-7) against cocaethylene is
the same as the most efficient mutant against norcocaine and (-)-cocaine. E12-7 has an
861-fold improved catalytic efficiency against cocaethylene, 1080-fold improved
catalytic efficiency against norcocaine, and a 2020-fold improved catalytic efficiency
against (-)-cocaine. So, E12-7 is identified as the most promising enzyme (BChE mutant)
for metabolizing all of the three toxic substrates: cocaethylene, (-)-cocaine, and
norcocaine.
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Table 3.1 Kinetic parameters determined in vitro for (-)-cocaine, norcocaine and
cocaethylene hydrolyses catalyzed by wild-type BChE and its mutants.
Substrate

(-)-Cocaineb

Norcocaineb

Cocaethylenec

Enzymea

KM (µM)

kcat (min-1)

kcat/KM (M-1min-1)

RCEd

WT BChE

4.5

4.1

9.11 × 105

1

E14-3

3.1

3,060

9.87 × 108

1,080

E12-7

3.1

5,700

1.84 × 109

2,020

WT BChE

15

2.8

1.87 × 105

1

E14-3

12

766

6.38 × 107

343

E12-7

13

2,610

2.01 × 108

1,080

WT BChE

7.5

3.3

4.40 × 105

1

E14-3

8.0

1,820

2.28 × 108

517

E12-7

9.5

3,600

3.79 × 108

861

a

The enzyme under the study was wild-type human BChE (WT BChE),
A199S/S287G/A328W/Y332G
mutant
(E14-3),
or
A199S/F227A/S287G/A328W/Y332G mutant (E12-7).
b
Data for wild-type BChE against (-)-cocaine came from reference (79), data for E14-3
against (-)-cocaine came from reference (88), data for E12-7 against (-)-cocaine came
from reference (76), and data for all enzymes against norcocaine came from reference
(116).
c
All of the kinetic data for cocaethylene were determined in the present study for the first
time.
d
RCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM value
of the mutant to that of wild-type BChE against the same substrate.

In addition, we also wanted to know whether alcohol has a significant effect on the
catalytic activity of the enzymes examined in this study. For this purpose, the catalytic
efficiency of E14-3 (as an example) for cocaine hydrolysis was determined in the
presence of alcohol (800 mg/dL) in comparison with the corresponding activity in the
absence of alcohol. The data depicted in Figure 3.6 revealed that alcohol (even at the
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concentration as high as 800 mg/dL or 0.174 M) does not significantly affect the enzyme
activity.

Figure 3.6 Kinetic data obtained in vitro for E14-3-catalyzed hydrolysis of (-)-cocaine in
the absence and presence of alcohol, showing that alcohol with the concentration as high
as 800 mg/dl or 0.174 M does not signiﬁcantly modify the catalytic efﬁciency of the
enzyme. The concentrations of the enzyme used for the two experiments were exactly the
same. The changes in the UV absorption at 230 nm represent the changes in the cocaine
concentrations.

3.5 Cocaethylene clearance accelerated by E12-7
Our recently reported in vivo studies (116, 123) have demonstrated that E12-7 can
efficiently metabolize (-)-cocaine and norcocaine in rats. In light of the encouraging in
vitro activity data discussed above, we would like to know whether E12-7 can also
efficiently metabolize cocaethylene in rats. We characterized the pharmacokinetic
profiles of cocaethylene clearance with and without the presence of E12-7 in rats. Four
rats (n=4) were injected with saline, followed by i.v. injection of 3 mg/kg cocaethylene.
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Another set of four rats (n=4) were injected with 0.15 mg/kg E12-7, followed by i.v.
injection of 3 mg/kg cocaethylene. The E12-7 dose was 0.15 mg/kg which led to an E127 concentration of ~3 mg/L (which is about a half of the average concentration of the
endogenous BChE in human, see discussion below) in plasma at ~2 min after the i.v.
injection of E12-7 according to our previous study.(123) For each rat, the blood was
sampled at 2, 5, 15, 30, 60, 90, 120, 150, and 180 min after the cocaethylene injection.
The in vivo data are depicted in Figure 3.7.
E12-7 can hydrolyze cocaethylene to produce benzoic acid and ecgonine ethyl ester,
and greatly accelerate the clearance of cocaethylene from the body. The control curves in
Figure 3.7 reflect the overall effects of all possible cocaethylene elimination
pathways.(99) As seen in Figure 3.7, in the control rats, the average concentration of
cocaethylene at the first time point (2 min) was ~2.7 μM, while the average concentration
of benzoic acid (metabolite) was ~0.3 μM. In the presence of E12-7, the average
concentration of cocaethylene at ~2 min in the blood sample was below the detectable
level (~0.1 μM, see Figure 3.7A), while the average concentration of benzoic acid at the
first time point (2 min) was ~7.4 μM (Figure 3.7B). Most of the cocaethylene was
hydrolyzed by E12-7 between the i.v. cocaethylene injection and the first blood sampling
at 2 min after the injection. The E12-7-caused dramatic changes in both the cocaethylene
and benzoic acid concentrations clearly indicated that cocaethylene was metabolized
rapidly to benzoic acid in the presence of E12-7. Notably, as shown in Figure 3.7B, the
benzoic acid concentration in plasma decreased with time. This is because most of the
cocaethylene had already been hydrolyzed by E12-7 before the first time point (2 min) so
that further generation of benzoic acid after 2 min was negligible compared to the
benzoic acid elimination from plasma.
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Figure 3.7 Cocaethylene clearance accelerated by E12-7. Time-dependent concentrations
of cocaethylene (A) and benzoic acid (B) in blood. Benzoic acid is the product of E12-7catalyzed hydrolysis of cocaethylene. Saline or 0.15 mg/kg E12-7 was injected i.v. in rats
(n=4) 1 min before the i.v. injection of 3 mg/kg cocaethylene.

It should be mentioned that the total plasma concentration of cocaethylene and
benzoic acid (~7.5 μM) in the presence of E12-7 (when the benzoic acid concentration
was higher) was higher than that (3.0 μM) in the absence of E12-7 (when the
cocaethylene concentration was higher). This observation might be associated with the
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potentially different distribution volumes of cocaethylene and benzoic acid in the body.
Cocaethylene is an amine drug which can readily cross cell membranes under
physiological condition, while benzoic acid primarily exists in the benzoate ion state
under the physiological conditions. So, benzoic acid is expected to have a relatively
smaller distribution volume compared to cocaethylene.

3.6 Effects of E12-7 on the pharmacokinetics of (-)-cocaine and cocaethylene
With E12-7 identified as the most active enzyme (BChE mutant) for cocaethylene in
addition to its previously known high catalytic activities for (-)-cocaine and norcocaine,
we further carried out kinetic modeling of cocaine metabolism using the kinetic equations
shown in Figure 3.2 in the presence of alcohol and three enzymes: CocH (which refers to
either wild-type human BChE or E12-7) in human plasma; hCE-1; and CYP 3A4.
Concerning CocH, a typical adult has a blood volume of ~5 L.(82) Previously reported
concentrations of endogenous BChE protein in human plasma ranged from 4 to 7 mg/L
(128-130), giving an average value of ~6 mg/L or ~0.07 M in terms of the total BChE
protein concentration (denoted as [E]), assuming that a tetramer of human BChE has four
active sites.(131, 132) According to the kinetic data summarized in Table 3.1, we should
have Vmax = 0.29 M min-1 and KM = 4.5 M for the wild-type BChE against (-)-cocaine,
and V´max = 0.23 M min-1 and K´M = 7.5 M for the wild-type BChE against
cocaethylene, and Vmax = 0.20 M min-1 and KM = 15 M for the wild-type BChE
against norcocaine, when [E] = 0.07 M. These kinetic parameters were used in our
modeling with the wild-type BChE. Similarly, for E12-7, according to the kinetic data
summarized in Table 3.1, we should have Vmax = 400 M min-1 and KM = 3.1 M against
(-)-cocaine, V´max = 250 M min-1 and K´M = 9.5 M against cocaethylene, and Vmax =
180 M min-1 and KM = 13 M against norcocaine, when [E] = 0.07 M.
For (-)-cocaine transesterification to cocaethylene in the presence of a sufficiently
high concentration of alcohol, it has been known that hCE-1 and its (-)-cocaine
transesterification-specific activity exist in not only liver, but also other tissues. (-)Cocaine transesterification-specific activity in isolated kidney microsomes was even
greater than that measured in the liver microsomes.(133) It has also been known that (-)cocaine can diffuse in the body very rapidly to reach the equilibrium.(82) It is reasonable
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to assume that (-)-cocaine, cocaethylene, and norcocaine distributions in the blood and
other tissues can rapidly reach the equilibrium during the metabolic reactions. Thus, it
was roughly estimated that F1 = 12.5 M min-1 and k1 = 0.56 mM for (-)-cocaine
transesterification to cocaethylene, according to the available experimental data including
the enzyme activity (134) and the enzyme distribution in the body (127) and an
assumption that the average hCE-1 density in the whole human body is ~50% of the
hCE-1 density in the human liver. Similarly, it was estimated that F2 = 14.4 M min-1 and
k2 = 2.7 mM for the enzymatic oxidation of (-)-cocaine to norcocaine.(116) These
roughly estimated kinetic parameters were used in our kinetic modeling with various
initial concentrations; our additional modeling tests revealed that kinetic modeling using
different values of the catalytic parameters would lead to the same qualitative conclusions
mentioned below.
The first set of initial concentrations used in the kinetic modeling include: A(0) (the
initial concentration of (-)-cocaine) = 1 to 100 M while B(0) (the initial concentration of
cocaethylene) = 0 and F(0) (the initial concentration of norcocaine) = 0. Depicted in
Figure 3.8 are the time-dependent concentrations of (-)-cocaine, cocaethylene and
norcocaine when A(0) = 10 M in the presence of alcohol, hCE-1, CYP 3A4 and wildtype human BChE (Figure 3.8A to C) or alcohol, hCE-1, CYP 3A4 and E12-7 (Figure
3.8D to F). As seen in Figure 3.8A to C, in the presence of alcohol, hCE-1, CYP 3A4 and
wild-type human BChE (without administration of any exogenous enzyme), (-)-cocaine
has an area under the curve (AUC) of 178 μM·
min and a half-life (t1/2) of 14 min,
cocaethylene has an AUC of 152 μM·
min and a half-life of 67 min, and norcocaine has
an AUC of 37 μM·
min and a half-life of 99 min. The modeling data suggest that
cocaethylene can exist in the body for a much longer time compared to (-)-cocaine itself
because the endogenous wild-type BChE has a relatively lower catalytic activity against
cocaethylene.
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Figure 3.8 Kinetics of (-)-cocaine and its metabolites in the presence of alcohol and
various enzymes. The modeled concentrations (in silico data) of (-)-cocaine (A),
cocaethylene (B), and norcocaine (C) in human blood when the initial (-)-cocaine
concentration is 10 M in the presence of alcohol, hCE-1, CYP 3A4 and wild-type
human BChE, and concentrations of (-)-cocaine (D), cocaethylene (E), and norcocaine (F)
in human blood when the initial (-)-cocaine concentration is 10 M in the presence of
alcohol, hCE-1, CYP 3A4 and E12-7.
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Based on the kinetic modeling, cumulatively, about 39% of (-)-cocaine has been
metabolized to cocaethylene and then ecgonine ethyl ester and benzoic acid when A(0) =
10 μM. Further, the modeling data summarized in Table 3.2 indicate that percentage
contribution of (-)-cocaine transesterification to cocaethylene, as well as the AUC and t1/2
of (-)-cocaine, cocaethylene and norcocaine, should increase with increasing the initial ()-cocaine concentration. The data of the kinetic modeling are in reasonable agreement
with the experimental observations that ~18% to ~34% of cocaine is converted to
cocaethylene through transesterification when the peak concentration of cocaine in
human plasma is 1 to 2 μM. According to the modeling data in Table 2, when A(0) = 1 or
2 μM, about 27% or 29% of (-)-cocaine has been converted to cocaethylene and then
ecgonine ethyl ester and benzoic acid.
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Table 3.2 Kinetic parameters obtained from in silico modeling for (-)-cocaine and
norcocaine hydrolyses catalyzed by wild-type human BChE and its mutants. A(0) is the
initial concentration of (-)-cocaine. Coca% refers to the percentage contribution of (-)cocaine metabolism through hCE-1-catalyzed transesterification to cocaethylene. Coc,
Coca, and Norc represent (-)-cocaine, cocaethylene, and norcocaine, respectively.
hCE-1, CYP 3A4, and wild-type BChE
A(0)

AUC(μM·min)

(μM) Coc

t1/2(min)

hCE-1, CYP 3A4, and E12-7

Coca%

Coca

Norc

Coc

Coca

Norc

AUC(μM·min)

t1/2(min)

Coca%

Coc

Coca

Norc

Coc

Coca

Norc

1

12

8.9

2.5

8.5

54

91

27%

0.009

0.000

0.000

0.007

0.051

0.078

0.02%

2

26

19

5.3

9.3

56

92

29%

0.021

0.000

0.000

0.008

0.053

0.079

0.03%

3

41

31

8.4

10

57

93

30%

0.035

0.000

0.000

0.009

0.054

0.081

0.03%

4

58

44

12

11

59

94

32%

0.051

0.000

0.000

0.010

0.056

0.083

0.03%

5

75

59

15

11

60

95

33%

0.070

0.000

0.000

0.011

0.057

0.084

0.03%

6

94

74

19

12

62

96

35%

0.092

0.000

0.000

0.013

0.058

0.086

0.03%

7

114

92

23

13

63

97

36%

0.116

0.000

0.000

0.014

0.060

0.088

0.04%

8

134

110

28

13

64

98

37%

0.142

0.000

0.000

0.015

0.062

0.089

0.04%

9

155

130

32

14

66

99

38%

0.171

0.000

0.000

0.016

0.064

0.091

0.04%

10

178

152

37

14

67

99

39%

0.203

0.000

0.000

0.018

0.066

0.093

0.05%

20

432

451

91

17

83

107

47%

0.656

0.001

0.000

0.030

0.083

0.111

0.07%

30

728

925

156

19

100

114

53%

1.359

0.001

0.000

0.042

0.100

0.129

0.10%

40

1051

1599

229

21

117

119

56%

2.312

0.002

0.000

0.055

0.117

0.147

0.12%

50

1395

2495

310

22

134

124

59%

3.514

0.003

0.001

0.068

0.134

0.165

0.15%

60

1755

3627

398

23

151

129

62%

4.965

0.004

0.001

0.079

0.150

0.183

0.17%

70

2129

5007

493

24

169

133

64%

6.665

0.005

0.001

0.093

0.166

0.200

0.20%

80

2515

6642

594

25

187

137

65%

8.614

0.007

0.002

0.104

0.182

0.217

0.22%

90

2912

8540

702

26

206

141

66%

10.81

0.008

0.002

0.117

0.198

0.234

0.24%

100

3319

10705

817

26

224

145

68%

13.26

0.010

0.002

0.130

0.213

0.250

0.27%
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In the presence of alcohol, hCE-1, CYP 3A4 and E12-7 (exogenous enzyme with [E]
= 0.07 M), when A(0) = 10 μM, (-)-cocaine only has an AUC of 0.203 μM·min and a
half-life of 0.018 min, and both cocaethylene and norcocaine have the AUC values
smaller than 0.001 μM·min, as shown in Figure 3.8D to F. Both the AUC and t1/2 values
are all negligible when E12-7 is administered as an exogenous enzyme (or provided via
gene therapy (135)) with the E12-7 concentration being the same as that of the
endogenous BChE ([E] = 0.07 M). As seen in Table 3.2, for all of the three toxic
compounds, i.e. (-)-cocaine, cocaethylene and norcocaine, the AUC and t1/2 increase with
increasing the initial (-)-cocaine concentration, but not dramatically. In particular, even if
A(0) = 100 M, the half-life of (-)-cocaine is still only 0.130 min, and the half-life of
cocaethylene is still only 0.213 min in the presence of E12-7. Clearly, all of the three
toxic compounds can be eliminated effectively and rapidly at the same time when E12-7
is administered as an exogenous enzyme with the E12-7 concentration being the same as
that of the endogenous BChE ([E] = 0.07 M) in the simplified kinetic model.
The initial concentrations used in the above kinetic modeling may represent the
possible cocaine abuse treatment conditions in which E12-7 is administered prior to the
cocaine administration. For possible cocaine overdose treatment using an exogenous
cocaine-metabolizing enzyme, the cocaine abusers have already taken cocaine and
alcohol, and converted some cocaine to cocaethylene and norcocaine before the enzyme
administration. In order to know whether E12-7 is also efficacious in hydrolysis of
cocaethylene, in addition to (-)-cocaine and norcocaine, for the cocaine overdose
treatment, we performed an additional, simplified kinetic modeling by assuming that 34%
(-)-cocaine has been converted to cocaethylene, 5% (-)-cocaine has been converted to
norcocaine, and 61% (-)-cocaine remains as (-)-cocaine when t = 0. Depicted in Figure
3.9 are data obtained from the simplified kinetic modeling when A(0) = 61 μM, B(0) = 34
μM, and F(0) = 5 μM. As seen in Figure 3.8A to C, in the absence of E12-7, (-)-cocaine
and cocaethylene may last in the body for a long time (>200 min). As seen in Figure 3.8D
to F, in the presence of 0.07 μM E12-7, all of the three toxic compounds may be
eliminated completely in ~0.2 min. These data qualitatively suggest that E12-7 should be
effective for cocaine overdose treatment even in the case of combined use of cocaine and
alcohol.
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Figure 3.9 The modeled concentrations (in silico data) of (-)-cocaine, cocaethylene, and
norcocaine in human blood when the initial concentrations of (-)-cocaine, cocaethylene,
and norcocaine are 61, 34, and 5 M, respectively. (A) to (C) refer to the time-dependent
concentrations in the presence of wild-type human BChE (without E12-7), whereas (D)
to (F) refer to the time-dependent concentrations in the presence of 0.07 μM E12-7.

61

3.7 Conclusion
The catalytic activity of human BChE and two BChE mutants (E14-3 and E12-7) for
cocaethylene has been characterized in comparison with the corresponding catalytic
activity for cocaine. The kinetic data reveal that wild-type human BChE has a relatively
lower catalytic activity against cocaethylene (kcat = 3.3 min-1, KM = 7.5 M, and kcat/KM =
4.40 × 105 M-1 min-1) compared to its catalytic activity against (-)-cocaine (kcat = 4.1 min-1,
KM = 4.5 M, and kcat/KM = 9.11 × 105 M-1 min-1). It has been shown that E14-3 and E127 have not only a considerably improved catalytic efficiency against cocaine and
norcocaine, but also a considerably improved catalytic efficiency against cocaethylene,
compared to the wild-type BChE. The most efficient enzyme (E12-7, i.e. the
A199S/F227A/S287G/A328W/Y332G mutant of human BChE) against cocaethylene is
the same as the most efficient one against norcocaine in addition to the known high
catalytic activity against (-)-cocaine. E12-7 has an 861-fold improved catalytic efficiency
against cocaethylene (kcat = 3600 min-1, KM = 9.5 M, and kcat/KM = 3.79 × 108 M-1 min-1).
Thus, E12-7 is identified as the most promising enzyme for hydrolyzing for all three
toxic compounds, i.e. (-)-cocaine, cocaethylene and norcocaine. It has been demonstrated
that E12-7 as an exogenous enzyme can indeed rapidly metabolize cocaethylene, in
addition to cocaine and norcocaine, in rats. Further kinetic modeling has suggested that
E12-7 with a concentration similar to that of the endogenous BChE in human plasma can
effectively eliminate all of the three toxic compounds in simplified kinetic models of
cocaine abuse and overdose associated with the concurrent use of cocaine and alcohol.
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Chapter Four: Evaluation of the Catalytic Activity of E12-7 against Cocaine in the
Presence of Commonly Used Small-Molecule Drugs

Summary
BChE was once called ―nonspecific cholinesterase‖ due to its wide range of
substrates and inhibitors. The effect of BChE and its mutants on cocaine metabolism
could possibly be reversed by some BChE inhibitors. Therefore, it is necessary to know
the inhibitory activity of various small-molecule drugs against BChE and its mutants.
Four classes of drugs intimately involved in cocaine abuse and its treatment are included
in this study. For the investigation described in this chapter, possible drug-drug
interactions between the promising BChE mutant E12-7 and some commonly used
therapeutic agents were examined in vitro for the first time in order to know whether the
examined therapeutic agents would significantly affect the catalytic activity of E12-7
against cocaine when they are co-administered with the enzyme. Most of the agents
examined did not show significant inhibition on E12-7. However, some tricyclic
antidepressants (TCA) were found as inhibitors of E12-7 with Ki in the range of 0.241.22 μM. Besides, TCA appeared to enhance cocaine-induced toxicity and, therefore,
should be avoided or used with caution when BChE or its mutant is applied for cocaine
abuse treatment.

4.1 The importance of drug-enzyme interaction study
Adverse drug reaction is one of the major causes of morbidity and mortality.(136)
Drug-enzyme interaction study could benefit clinical outcomes and safety of medication
treatments, especially for the high-risk and challenging population.
In comparison with the high selectivity of AChE, BChE was once called
―nonspecific cholinesterase‖ due to its wide range of substrates and inhibitors, including
acetylcholine, butyrylcholine, succinylcholine, cocaine, aspirin, organophosphates and
cholinesterase inhibitors for Alzheimer’s disease treatment.(73, 137, 138) The effect of
BChE and its mutants on cocaine metabolism could possibly be reversed by some potent
BChE inhibitors. Therefore, it is interesting to know the inhibitory activity of various
types of small-molecule drugs on the enzymes. Four classes of drugs intimately involved
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in cocaine abuse or its treatment are chosen in this study, including the drugs possibly coabused with cocaine, medications for the treatment of those co-abused drugs, the current
medications used for cocaine overdose treatment in emergency department, or the
possible medications used to alleviate the symptoms of cocaine withdrawal. To be
specific, there are several stimulants might co-abused with cocaine, such as alcohol,
nicotine, caffeine, heroin (its metabolite morphine), and methamphetamine. It is
necessary to know whether the co-abused drugs and the medications prescribed for those
co-abused drugs would affect the catalytic activity of the enzyme against cocaine.
Besides, although there are no medications available specific for cocaine, medications
such as fast-onset benzodiazepines and phentolamine are given to patients to control
cocaine overdose-induced symptoms in the emergency department.(46) When come to
cocaine withdrawal, depression is one of the major symptoms. The medications effective
in depression treatment might also alleviate the symptoms of cocaine withdrawal. In light
of the promising data obtained from the previous chapters, E12-7 may be developed as a
valuable therapeutic enzyme for cocaine abuse treatment. When necessary, the
combination of enzyme therapy and currently existing treatments might give a better
clinical outcome and, therefore, it is necessary to know whether those existing
medications would compromise the enzymatic activity.
In this study, possible drug-drug interactions between E12-7 and some commonly
used therapeutic agents were examined in vitro for the first time in order to know whether
the examined therapeutic agents would significantly affect the catalytic activity of E12-7
against cocaine when they are co-administered. Although the in vitro study could not
represent what really happens in human body, it can give us some insights into the
potential drug interactions which may occur in people.

4.2 Materials and methods
4.2.1 Enzyme preparation and other materials
E12-7 enzyme materials used for in vitro studies was prepared in our recently
reported study (123) developing and using stable CHO-S cells. The protein was purified
by using a two-step purification procedure (ion exchange chromatography followed by
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affinity chromatography), as described previously in detail.(116) The purified protein
was dialyzed against phosphate-buffered saline and stored at -80°C.
[3H](-)-cocaine (20-50 Ci/mmol) was purchased from PerkinElmer Life and
Sciences (Waltham, MA). Other drugs were obtained from Sigma-Aldrich (St. Louis,
MO), National Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD)
and Tocris Bioscience (Minneapolis, MN). Dimethy sulfoxide, and ethanol were used to
dissolve the drugs only when water failed and only at concentrations that shown not to
interfere with enzyme activity.

4.2.2 In vitro activity assays
For determining the catalytic activity of the E12-7 against (-)-cocaine in the absence
or presence of commonly co-administered drugs, we used a sensitive radiometric assay
based on toluene extraction of [3H](-)-cocaine labeled on its benzene ring (99). In brief,
E12-7 (10 ng/mL) was incubated with the tested drug in 0.1 M phosphate buffer (pH 7.4)
for 15 min at 25oC, and then varying concentrations of (-)-cocaine (mixed with trace
amount of [3H](-)-cocaine) was added to initiate the enzymatic reaction. The reactions
were stopped by adding 200 l of 0.1 M HCl, which neutralized the liberated benzoic
acid while ensuring a positive charge on the residual (-)-cocaine. [3H]benzoic acid (a
product of (-)-cocaine hydrolysis) was extracted by 1 ml of toluene and measured by
scintillation counting. Finally, the measured (-)-cocaine concentration-dependent
radiometric data were analyzed by using the standard Michaelis-Menten kinetics so that
the catalytic parameters were determined.
IC50 values of some compounds for E12-7 were determined by using a similar assay.
5 M (-)-cocaine was used as the substrate. Compounds were tested in the range of 0.04
– 20 M for amitriptyline and doxepin, 0.1–32 M for nortriptyline, 1–400 M for
ketamine, 2–800 M for naloxone, and 10–4000 M for methamphetamine. IC50 was
calculated using GraphPad Prism software, and Ki for a competitive inhibitor was
converted from obtained IC50 by the Cheng-Prusoff equation.(139)

[ ]
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4.3 Drug-E12-7 interaction
Four classes of drugs that most intimately involved in cocaine abuse and its
treatment were chosen in the study: I) the drugs usually co-abused with cocaine; II)
medications approved for those co-abused drugs; III) the medications used for cocaine
overdose treatment in emergency room; IV) the possible medications used to alleviate the
symptoms of cocaine withdrawal. These drug concentrations represent 1/10, 1/3 and 1×
the pharmacologically relevant blood concentrations in human. The 1× drug level
represents the peak blood or plasma concentration of the drug (Cmax or Css) when taking
the maximum recommended dose.

4.3.1 Class I: Drugs commonly co-abused with cocaine
Six

possibly

co-abused

drugs,

including

alcohol,

nicotine,

morphine,

methamphetamine, caffeine and ketamine were chosen as the representative of this class.
The pharmacological blood concentrations of drugs were from the study of Brim et al.
(140) and the wikipedia (caffeine). Nicotine, morphine and caffeine did not show any
inhibition at the examined concentrations, while methamphetamine and ketamine
demonstrated slight inhibition on E12-7 only at the maximum concentration of the drugs
(Table 4.1).
The effect of alcohol was discussed in Chapter Three, and E14-3 was used as an
example. The catalytic efficiency of E14-3 for cocaine hydrolysis was determined in the
presence of alcohol in comparison with the corresponding activity in the absence of
alcohol. The data depicted in Figure 3.6 revealed that alcohol (even at the concentration
as high as 800 mg/dL or 0.174 M) does not significantly affect the enzyme activity.
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Table 4.1 Class I drug concentrations and tested interactions with E12-7. kcat and KM were
determined for three separate experiments. ns: no significant interaction found.
Pharmacological
blood or plasma
concentrations
0 μM
0.12 μM
0.36 μM
1.2 μM

kcat
(min-1)

KM
(μM)

kcat/KM
(μM-1 min-1)

Significant
interaction

5700
5660
5620
5700

3.10
3.01
2.99
2.97

1840
1880
1880
1920

ns

Morphine

0 μM
0.18 μM
0.54 μM
1.8 μM

5700
5570
5530
5750

3.10
3.12
2.98
3.09

1840
1790
1860
1860

ns

Methamphetamine

0 μM
6.7 μM
20.1 μM
67 μM

5700
5800
5610
5550

3.10
3.37
3.37
4.31

1840
1720
1660
1290

Caffeine

0
5.15 μM
15.4 μM
51.5 μM

5700
5720
5700
5800

3.10
3.13
3.11
3.21

1840
1830
1830
1810

Ketamine

0
0.35 μM
1.05 μM
3.5 μM

5700
5780
5730
5720

3.10
3.12
3.21
4.16

1840
1850
1780
1380

Drugs

Nicotine

ns

4.3.2 Class II: Medications approved for the commonly co-abused drugs with
cocaine
There are several medications available on market for treatment of alcohol, nicotine,
and opioid abuse. For example, disulfiram is one of the drugs for treatment of chronic
alcoholism by inhibition of acetaldehyde dehydrogenase. Varenicline, as a nicotinic
receptor partial agonist, is a prescription medication used to treat nicotine addiction.
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Naltrexone, as an opioid receptor antagonist, is primarily used for the management of
alcohol dependence and opioid dependence, such as heroin or morphine. Naloxone is a
pure opioid antagonist and used to counter the effects of opioid overdose. The
pharmacological blood concentrations of drugs (1×) were from the studies.(140-142)
According to the data shown in Table 4.2, the kinetic parameters of E12-7 for
cocaine hydrolysis were not altered by those compounds, except for naloxone at the
highest concentration of 10 μM causing slight increase in KM value and decrease in
catalytic efficiency of E12-7, compared with the parameters of E12-7 in the absence of
drugs.

Table 4.2 Class II drug concentrations and tested interactions with E12-7. kcat and KM
were determined for three separate experiments. ns: no significant interaction found.
Pharmacological
blood or plasma
concentrations
0
25 nM
75 nM
250 nM

kcat
(min-1)

KM
(μM)

kcat/KM
(μM-1 min-1)

Significant
interaction

5700
5970
5900
5950

3.10
3.11
2.99
3.14

1840
1920
1970
1900

ns

Naloxone

0
1 μM
3 μM
10 μM

5700
5550
5480
5250

3.10
3.02
3.18
4.27

1840
1840
1720
1230

Varenicline

0
1.89 nM
5.69 nM
18.9 nM

5700
5540
5500
5590

3.10
3.09
3.02
3.09

1840
1790
1820
1810

ns

Disulfiram

0
0.14 μM
0.42 μM
1.4 μM

5700
5660
5610
5700

3.10
2.98
3.00
3.04

1840
1900
1870
1880

ns

Drugs

Naltrexone
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4.3.3 Class III: Medications used for cocaine overdose treatment in emergency
department
Although there is no medication available specific for cocaine so far, a standard
protocol in emergency department is employed mainly to treat patients by relieving
cocaine-induced symptoms, especially chest pain and possible heart attack. Fast-onset
benzodiazepines (diazepam, and midazolam) and phentolamine are the first line
medications for cocaine overdose treatment. The 1× drug concentrations are from the
package insert for REGITINE® (phentolamine mesilate) and studies (140, 143, 144).
In light of the promising data obtained from the previous chapters, E12-7 may be
developed as a valuable therapeutic enzyme for cocaine abuse treatment. The
combination of enzyme therapy and current treatments might give a better clinical
outcome, therefore, it is necessary to know whether those existing medications would
compromise the enzymatic activity. Fortunately, the tested drugs in Table 4.3, including
diazepam, oxazepam (a metabolite of diazepam), midazolam, and phentolamine, did not
show any significant inhibitory activity on E12-7 for cocaine hydrolysis.
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Table 4.3 Class III drug concentrations and tested interactions with E12-7. kcat and KM
were determined for three separate experiments. ns: no significant interaction found.
Pharmacological
blood or plasma
concentrations
0
0.81 μM
2.43 μM
8.1 μM

kcat
(min-1)

KM
(μM)

5700
5990
6060
5840

3.10
3.18
3.27
3.52

1840
1880
1850
1660

ns

Oxazepam

0 μM
0.21 μM
0.63 μM
2.09 μM

5700
5720
5690
5750

3.10
3.16
3.12
3.13

1840
1810
1820
1840

ns

Midazolam

0
0.64 μM
1.90 μM
6.4 μM

5700
5660
5670
5520

3.10
3.03
3.14
3.17

1840
1870
1810
1740

ns

Phentolamine

0
39.1 nM
117 nM
391 nM

5700
5850
5880
5800

3.10
3.03
3.09
3.21

1840
1930
1900
1810

ns

Drugs

Diazepam

kcat/KM
Significant
-1
-1
(μM min ) interaction

4.3.4 Class IV: Medications that could be used to alleviate the symptoms of cocaine
withdrawal
Depression is one of the major symptoms of cocaine withdrawal. Hence, the
medications effective in depression treatment might also alleviate the symptoms of
cocaine withdrawal. Tricyclic antidepressants (TCA, such as doxepin, amitriptyline and
nortriptyline) and monoamine oxidase inhibitors (phenelzine) are the important classes of
antidepressants. The 1× drug concentrations are based on the package insert for NARDIL
(phenelzine sulfate) and Nortriptyline hydrochloride, as well as the known studies (145,
146).
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Among the drugs on the list, amitriptyline and doxepin significantly affect the
catalytic activity of E12-7 against cocaine when they are co-administered, which is
consistent with the report about amitriptyline.(73, 147, 148) TCA share the similar
chemical structure with each other (shown in Figure 4.1), and also have the similarity as
the structure of BChE inhibitors reported by Zheng et al.(149) Therefore, it is not
surprising to note that doxepin and nortriptyline also inhibit the catalytic activity of E127 for cocaine hydrolysis.

Table 4.4 Class IV drug concentrations and tested interactions with E12-7. kcat and KM
were determined for three separate experiments. ns: no significant interaction found.
Pharmacological
blood or plasma
concentrations
0
8.45 nM
25.4 nM
84.5 nM

kcat
(min-1)

KM
(μM)

5700
5700
5870
5740

3.10
3.20
3.26
3.26

1840
1780
1800
1760

Doxepin

0
71.6 nM
215 nM
716 nM

5700
5960
5790
5340

3.10
3.94
4.99
8.37

1840
1510
1160
640

Amitriptyline

0
90.1 nM
270 nM
901 nM

5700
5740
5840
6000

3.10
3.64
5.83
12.20

1840
1580
1000
490

Nortriptyline

0
57 nM
171 nM
570 nM

5700
5780
5930
5900

3.10
3.28
3.78
4.84

1840
1760
1570
1220

Drugs

Phenelzine
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kcat/KM
Significant
(μM-1 min-1) interaction

ns

Doxepin

Amitriptyline

Nortriptyline

Figure 4.1 Chemical structures of doxepin, amitriptyline, and nortriptyline.

4.4 Inhibitory activities of compounds for E12-7
4.4.1 Doxepin, amitriptyline and nortriptyline for E12-7
According to the above kinetic parameters of E12-7, KM increased and kcat
decreased or increased slightly (less than 6.3% at the highest drug concentration) in the
presence of doxepin, amitriptyline, or nortriptyline. However, the change in kcat might be
due to the experimental errors, suggesting that these drugs are likely competitive
inhibitors.
The examined TCA including doxepin, amitriptyline, and nortriptyline exhibited
strong inhibition on E12-7 with Ki in the range of 0.24-1.22 μM, as shown in Table 4.5.
The overall binding of E12-7 with those three compounds may be similar to its binding
with BTC or cocaine. In general, as a tertiary or secondary amine, doxepin, amitriptyline,
and nortriptyline exist mainly in protonated form under physiological pH that resembles
choline. The positively charged quaternary ammonium group is bound to a choline
binding site and/or the tricyclic part interacts with the hydrophobic pocket of the
enzyme.(148, 150) The order of inhibitory potency is amitriptyline > doxepin >
nortriptyline for E12-7, which is probably due to the difference in their chemical
structures.

72

Table 4.5 IC50 and inhibitory constant Ki of compounds for E12-7.
Enzyme

Compound

IC50 (μM)

Ki (μM)

Plasma
Cmax (μM)

E12-7

Doxepin
Amitriptyline
Nortriptyline
Ketamine
Naloxone
Methamphetamine

0.73
0.62
3.19
15.9
24.8
258

0.28
0.24
1.22
6.08
9.50
98.6

0.72
0.90
0.57
3.5
10
67

Ki is defined as the concentration of inhibitor that is required to decrease the
maximum rate of the reaction by a half. If the Ki value is much larger than the maximum
plasma drug concentration from typical dosing, then the drug is not likely to inhibit the
activity of the enzyme. From the data in Table 4.5, the Ki values for doxepin and
amitriptyline for E12-7 are ~3-fold lower than the corresponding maximum drug
concentration in plasma. Thus, it is very likely that doxepin and amitriptyline slow down
the cocaine hydrolysis catalyzed by E12-7 and affect in vivo efficacy of E12-7 in cocaine
abuse treatment. Fortunately, amitriptyline is a reversible inhibitor of BChE (147), thus it
is expected that the enzyme activity will recover once the drug is cleared from plasma.
However, studies have shown that TCA appears to enhance cocaine-induced toxicity (38,
151) and, therefore, TCA should be used with caution when BChE or its mutant is
applied for cocaine abuse treatment.

4.4.2 Methamphetamine, ketamine, and naloxone for E12-7
The data in Table 4.1 and 4.2 have revealed that methamphetamine, ketamine, and
naloxone at their maximum drug concentrations increased the KM values and decreased
the catalytic efficiency of E12-7 by 30-40%. Their Ki values were further determined to
be 98.59 μM, 6.08 μM, and 9.5 μM, respectively (Table 4.5), which are a little higher
than or roughly equal to their corresponding maximum drug concentrations in plasma.
Therefore, methamphetamine, ketamine, and naloxone are likely to slightly affect the
catalytic activity of exogenous E12-7 in metabolism of cocaine.
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4.5 Conclusion
Four classes of drugs intimately involved in cocaine abuse and its treatment were
examined in this study. Most of the agents did not significantly inhibit E12-7. However,
some tricyclic antidepressants (TCA) examined in this study did inhibit E12-7 with Ki in
the range of 0.24-1.22 μM. Besides, TCA appears to enhance cocaine-induced toxicity,
therefore it should be avoided or used with caution when BChE or its mutant is applied
for cocaine abuse treatment. Fortunately, the current medications for cocaine overdose
treatment in the ED do not comprise the catalytic activity of E12-7 for cocaine hydrolysis.
Therefore the combination of enzyme therapy and current treatment for cocaine overdose
might be feasible and give a better clinical outcome. Additional in vivo studies in rodents
are necessary in order to predict the likelihood of drug-enzyme interactions in humans.

Copyright @ Shurong Hou 2014
74

Chapter Five: Characterization of a Highly Efficient New Mutant of Human
Butyrylcholinesterase Specific for Cocaine Detoxification

Summary
It

is

known

that

the

aforementioned

E12-7

(which

is

the

A199S/F227A/S287G/A328W/Y332G mutant of human BChE) has ~2000-fold
improved catalytic efficiency against (-)-cocaine compared to the wild-type BChE. It is
highly desirable to further improve the catalytic activity of the enzyme against (-)-cocaine
in order to decrease the required dose and also the cost for effective treatment of cocaine
abuse. Through a novel and systematic computational design approach using E12-7 as a
standard reference, a new BChE mutant (A199S/F227A/P285Q/S287G/A328W/Y332G),
denoted as E20-7, with further improved in vitro activity and in vivo potency compared to
E12-7 was designed and discovered. The in vitro catalytic activity of E20-7 against
cocaine and in vivo potency in metabolizing cocaine were well characterized in the study
described in this chapter. The newly discovered mutant E20-7 (kcat/KM = 4.1 × 109 M-1
min-1) shows 2.2-fold further improvement in catalytic efficiency against (-)-cocaine
compared to E12-7 (kcat/KM = 1.8 × 109 M-1 min-1), or 4,450-fold improved catalytic
efficiency against (-)-cocaine compared to the wild-type BChE (kcat/KM = 9.1 × 105 M-1
min-1). Extensive in vivo studies have demonstrated that E20-7 as an exogenous enzyme
can indeed rapidly metabolize cocaine in mice and rats, can protect mice from the acute
toxicity induced by a lethal dose of cocaine, and efficiently prevent cocaine from entering
CNS and producing the physiological effects. E20-7 is identified as the most efficient
cocaine hydrolase known so far, and may be developed as a valuable therapeutic agent
for cocaine abuse treatment.

5.1 Overview of the strategy to design and discover high-activity mutants of human
BChE
As well known, computational design of high-activity mutants of an enzyme is
extremely challenging, particularly when the chemical reaction process is ratedetermining for the enzymatic reaction.(92, 94, 95) To computationally design a mutant
enzyme with an improved catalytic activity for a given substrate, one needs to design
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possible amino-acid mutations that can accelerate the rate-determining step of the
catalytic reaction process (96, 150, 152) while other steps of the reaction are not slowed
down by the mutations. The fundamental reaction pathway for BChE-catalyzed
hydrolysis of (-)-cocaine was uncovered by extensive molecular dynamics (MD)
simulations (96, 150) and reaction-coordinate calculations (150, 152) using quantum
mechanics (QM) and hybrid quantum mechanics/molecular mechanics (QM/MM).(153157) The computational studies revealed that the rate-determining step of (-)-cocaine
hydrolysis catalyzed by the A328W/Y332A and A328W/Y332G mutants of BChE is the
first step of the chemical reaction process.(84, 92, 96, 150) Therefore, starting from the
A328W/Y332A or A328W/Y332G mutant, rational design of BChE mutants against (-)cocaine has been focused on decreasing the energy barrier for the first reaction step
without significantly affecting the other steps. Our research group has developed unique
computational strategies and protocols based on the virtual screening of rate-determining
transition states of the enzymatic reaction to design enzyme mutants with improved
catalytic activity.(76, 84-89) The computational design was followed by in vitro
experiments, including site-directed mutagenesis, protein expression, and enzyme activity
assays. The integrated computational-experimental studies have led to discovery of a
series of BChE mutants with a significantly improved catalytic efficiency against (-)cocaine (76, 84-89). The first one of our designed and discovered high-activity mutants
of human BChE, i.e. the A199S/S287G/A328W/Y332G mutant (84), was validated by an
independent group of scientists (90, 91). This human BChE mutant fused with albumin is
currently in double-blind, placebo-controlled clinical trial Phase II in humans by Teva
Pharmaceutical Industries Ltd for cocaine abuse treatment.(17) Our recently designed and
discovered new mutants (76, 89) of human BChE are even more active against (-)cocaine in vitro and in vivo. The designed BChE mutant E12-7 shows ~2,000-fold
improved catalytic efficiency against cocaine, compared to the wide-type BChE. The in
vivo data of previously designed BChE mutants indicates that the catalytic efficiency
correlates with their efficacy in practical protection effects from cocaine-induced acute
toxicity, which may guide the future direction of the rational design of high efficient
BChE mutants in order to further improve the efficacy in the cocaine abuse treatment.(88)
Since the costs for protein-based drugs are usually much higher than small-molecule
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based drugs, it is highly desirable to further improve the catalytic efficiency of the
enzyme against cocaine in order to decrease the required dose of the enzyme, and the
costs of the enzyme therapy as well. The general concept of the computational design
strategy (76, 84-89) was employed (using E12-7 as a standard reference) to design and
discover new BChE mutants with further improved catalytic efficiency against (-)cocaine.

5.2 In vitro characterization of E20-7 for their activities against (-)-cocaine and
acetylcholine
5.2.1 Materials and methods for in vitro studies
5.2.1.1 Materials used for in vitro studies
Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from
Stratagene (La Jolla, CA). [3H](-)-cocaine (50 Ci/mmol) was purchased from
PerkinElmer Life Sciences (Boston, MA). All oligonucleotides were synthesized by the
Eurofins MWG Operon (Huntsville, Alabama). The QIAprep Spin Plasmid Miniprep Kit
and Qiagen plasmid purification kit and QIAquick PCR purification kit were obtained
from Qiagen (Santa Clarita, CA). Chinese Hamster Ovary (CHO) cells were obtained
from Life Technologies (Grand Island, NY). 3, 3, 5, 5-Tetramethylbenzidine (TMB)
was obtained from Sigma (Saint Louis, Missouri). Anti-BChE (mouse monoclonal
antibody, Product # HAH002-01) was purchased from AntibodyShop (Gentofte,
Denmark) and goat anti-mouse IgG HRP conjugate was from Zymed (San Francisco,
CA).

5.2.1.2 Site-directed mutagenesis
Site-directed mutagenesis of human BChE cDNA was performed to get desired
mutations by using the QuickChange method (158). E20-7 cDNA was generated by
performing polymerase chain reaction (PCR) with Pfu polymerase, using E12-7 cDNA in
a pRc/CMV expression plasmid as the template and primers designed for P285Q
mutation. The primers used for P285Q mutation were as follows (the bases corresponding
to introduced mutation are shown in bold):
F-primer GTT GTC CCC TAT GGG ACT CAG TTG TCA GTA AAC TTT GGT CCG ACC
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R-primer GGT CGG ACC AAA GTT TAC TGA CAA CTG AGT CCC ATA GGG GAC AAC

The PCR product was treated with Dpn I endonuclease to digest the parental DNA
template. Modified plasmid DNA was transformed into Escherichia coli, amplified, and
purified. The DNA sequences of the mutants were confirmed by DNA sequencing.

5.2.1.3 Protein expression
The enzymes, including wild-type BChE, E12-7, and E20-7, were expressed in
Chinese Hamster Ovary (CHO) cells. Cells at the density of ~1 × 106 cells/ml were
transfected by TransIT-PRO® Transfection Kit and cultured for five more days. The
medium was harvested for the BChE activity assays. The wild-type BChE, E12-7 and
E20-7 were expressed and their enzyme activity against (-)-cocaine were assayed at the
same time under the same experimental conditions. The wild-type BChE and E12-7 were
used as standard references.

5.2.1.4 Protein purification
Puriﬁcation of the enzyme in the medium was achieved by a two-step puriﬁcation
using ion-exchange chromatography followed by afﬁnity chromatography, as described
previously in detail.(116) The purified protein was dialyzed against phosphate-buffered
saline and stored at 4°C or -80°C.

5.2.1.5 Enzyme activity assays
To measure (-)-cocaine and benzoic acid, the product of (-)-cocaine hydrolysis
catalyzed by BChE, we used sensitive radiometric assays based on toluene extraction of
[3H](-)-cocaine labeled on its benzene ring (99). In brief, to initiate the enzymatic
reaction, 100 nCi of [3H](-)-cocaine was mixed with 100 l of culture medium. The
enzymatic reactions proceeded at room temperature (25oC) with varying concentrations
of (-)-cocaine. The reactions were stopped by adding 200 l of 0.1 M HCl, which
neutralized the liberated benzoic acid while ensuring a positive charge on the residual (-)cocaine. [3H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation
counting. Finally, the measured (-)-cocaine concentration-dependent radiometric data
were analyzed by using the standard Michaelis-Menten kinetics so that the catalytic
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parameters were determined along with the enzyme concentration determined by a wellestablished standard enzyme-linked immunosorbent assay (ELISA) protocol (84) and
also the Bradford assay with the two step-purified enzyme. The BChE activity assays
with [3H]ACh are similar to the assays with [3H](-)-cocaine. The primary difference is
that the enzymatic reaction was stopped by addition of 200 µl of 0.2 M HCl containing 2
M NaCl and that the product was [3H]acetic acid for the ACh hydrolysis.

5.2.2 In vitro activity of E20-7 against (-)-cocaine and ACh
Based on the computational design, we carried out in vitro experimental tests,
including site-directed mutagenesis, protein expression, and in vitro enzyme activity
assays, on wild-type BChE, E12-7 and E20-7 mutants of human BChE. To minimize the
possible systematic experimental errors of the in vitro kinetic data, we expressed the
enzymes and performed kinetic studies with wild-type BChE, E12-7 and E20-7 under the
same conditions and compared the catalytic efficiencies of E20-7 against (-)-cocaine and
ACh to the corresponding catalytic efficiencies of wild-type BChE and E12-7. MichaelisMenten kinetics of the enzymatic hydrolysis of (-)-cocaine or ACh was determined by
performing the sensitive radiometric assays using [3H](-)-cocaine (labeled on its benzene
ring) or [3H]ACh (labeled on its acetyl group) with varying concentrations of substrate.
Depicted in Figures 5.1 are the measured kinetic data of E20-7 for (-)-cocaine and ACh.
Summarized in Table 5.1 are the obtained kinetic parameters of E20-7 for hydrolysis of ()-cocaine and ACh in comparison with the known kinetic parameters of wild-type BChE
and E12-7 against (-)-cocaine and ACh.
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(A)

(B)

Figure 5.1 Kinetic data for (-)-cocaine (A) and ACh (B) hydrolysis catalyzed by E20-7.
The reaction rate was represented in M min-1 per nM enzyme.
As shown in Table 5.1, the newly discovered mutant E20-7 (kcat = 8790 min-1, KM =
2.2 M, and kcat/KM = 4.1 × 109 M-1 min-1) shows a 2.2-fold improvement in catalytic
efficiency against (-)-cocaine compared to E12-7 (kcat = 5700 min-1, KM = 3.1 M, and
kcat/KM = 1.8 × 109 M-1 min-1), or a 4,450-fold improved catalytic efficiency against (-)cocaine compared to the wild-type BChE (kcat = 4.1 min-1, KM = 4.5 M, and kcat/KM = 9.1
× 105 M-1 min-1). AChE has been recognized as the most efficient hydrolytic enzyme,
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with its catalytic activity for ACh (kcat = 702,000 min-1, KM = 90 µM, and kcat/KM = 7.8 ×
109 M-1 min-1) approaching the limit allowed by the diffusion of the substrate.(159, 160)
The obtained catalytic efficiency of E20-7 for (-)-cocaine hydrolysis is comparable to that
of AChE for ACh hydrolysis.
Compared to E12-7 (A199S/F227A/S287G/A328W/Y332G), the additional P285Q
mutation

in

E20-7

(A199S/F227A/P285Q/S287G/A328W/Y332G)

significantly

decreases the KM values and slightly increases the kcat of E20-7 against (-)-cocaine. The
new mutation P285Q should not produce any new hydrogen bonds in the transition state.
However, it may indirectly affect the existing hydrogen bonding between the carbonyl
oxygen of (-)-cocaine and the oxyanion hole (consisting of residuals G116, G117, and
S199) in the transition states, thus further stabilizing the transition states and improving
the catalytic activity for (-)-cocaine.

Table 5.1 Kinetic parameters determined in vitro for enzymatic hydrolysis of (-)-cocaine
and ACh.
Substrate

(-)-cocaine

Enzymea

KM
(μM)

kcat
(min-1)

kcat/KM
(M-1min-1)

RCEb

WT BChE c

4.5

4.1

9.1 × 105

1

E12-7

3.1

5700

1.8 × 109

2020

8790

9

4450

8

1

8

0.78

8

E20-7
WT BChE
ACh

E12-7

2.2
d

148

61200

37

11900

4.1 × 10
4.1 × 10
3.2 × 10

E20-7

29

20100

6.9 × 10

1.68

AChEe

90

702,000

7.8 × 109

19

a

Unless indicated otherwise, all kinetic parameters listed in this table were determined in
the present study.
b
RCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM value
of the mutant to that of wild-type BChE against the same substrate.
c
Data for wild-type BChE from reference.(79)
d
The kcat value for wild-type BChE was reported in reference.(100)
e
Data for AChE from reference.(160)
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Regarding the catalytic activity against ACh (shown in Figures 5.1), we obtained kcat
= 20,100 min-1 and KM = 29 µM for E20-7. Compared to the wild-type BChE (kcat/KM =
4.1 × 108 M-1 min-1), both E12-7 and E20-7 listed in Table 5.1 have significantly lower
kcat and KM values against ACh. Overall, the catalytic efficiency (kcat/KM = 6.9 × 108 M-1
min-1) of E20-7 against ACh is slightly higher than that of the wild-type BChE (~1.68fold).
Furthermore, it is interesting to notice that, the catalytic efficiency of wild-type
BChE against ACh (kcat/KM = 4.1 × 108 M-1 min-1) is ~450-fold higher than that of the
same enzyme against (-)-cocaine (kcat/KM = 9.1 × 105 M-1 min-1). However, for both E127 and E20-7, the catalytic efficiency against (-)-cocaine (kcat/KM = 1.8 × 109, 4.1 × 109 M1

min-1) is ~5-fold higher than that of the same enzyme against ACh (kcat/KM = 3.2 × 108,

6.9 × 108 M-1 min-1). As a result, E20-7 has not only a significantly improved catalytic
efficiency against (-)-cocaine, but also the desirable selectivity for (-)-cocaine over ACh.
It is known that ACh is the only natural substrate for both AChE and BChE in human
body.(161) However, it is unlikely that E20-7 administrated as an exogenous enzyme
would affect the motor transmission. First of all, the exogenous enzyme in plasma would
not enter the brain. Besides, E20-7 has a ~10-fold lower catalytic efficiency against ACh
than AChE, and peripheral cholinergic synapses are densely packed with AChE.

5.3 In vivo characterization of E20-7 for its potency in metabolizing cocaine
5.3.1 Materials and subjects for in vivo studies
Cocaine hydrochloride was provided by the National Institute on Drug Abuse
(NIDA) Drug Supply Program (Bethesda, MD) and prepared in saline for in vivo studies.
The benzoic acid used for the standard in the HPLC analysis was purchased through
Sigma Aldrich (St. Louis, MO). The E20-7 material used for in vivo studies were
prepared in our recently reported study (123) using stable CHO-S cells, purified using ion
exchange and affinity chromatography and diluted to the required concentration in
phosphate buffered saline (PBS) for injection.
Sprague-Darley (male or female) rats (200-250 g), male CD-1 mice, and Swiss
Webster male mice (27-30 g) were ordered from Harlan (Indianapolis, IN). The rats were
housed initially in 2 to 4 rats per cage. The mice were housed in groups of 2 to 5 mice per
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page. All the animals were allowed ad libitum access to food and water and were
maintained on a 12-hour light and dark cycle with lights on at 8 AM in a room kept at a
temperature of 21 to 22°C. Each animal was only used once. Experiments were
performed in the same colony room in accordance with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the National Institutes of Health. The
experimental procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Kentucky.

5.3.2 Characterization of cocaine clearance accelerated by E20-7
5.3.2.1 Animal procedure
Sprague-Darley rats (male, 200-250 g) were used in this study. General anesthetic
isoflurane was utilized with nose cone during the i.v. administration of enzyme E20-7 (or
PBS) and cocaine. To characterize cocaine (i.v. administrated) clearance accelerated by
E20-7, four rats were injected with PBS through tail vein 1 min before i.v. injection of 5
mg/kg cocaine, and other four rats were injected with the enzyme E20-7 followed by i.v.
injection of the same dose of cocaine. About 50 to 75 μl of blood from saphenous veins
was collected into capillary tubes and immediately mixed in 100 μl of 250 μM paraoxon
and 10 U heparin at 2, 5, 10, 15, 30, and 60 min after the i.v. injection of cocaine. To
characterize cocaine (i.p. administrated) clearance accelerated by E20-7, five rats were
injected with PBS through tail vein 1 min before i.p. injection of 25 mg/kg cocaine, and
other five rats were injected with the enzyme E20-7 followed by i.p. injection of the same
dose of cocaine. The blood was sampled at 5, 10, 15, 20, 30, 40, 60, 90, 120, and 150 min
after the i.p. administration of cocaine and treated with paraoxon. Paraoxon is an
irreversible BChE inhibitor that can stop the enzymatic hydrolysis of cocaine between
sampling and analysis. The diluted blood samples were stored at -70°C and assayed by
using a High-Performance Liquid Chromatographic (HPLC) method.
Benzoic acid is the product of cocaine hydrolysis catalyzed by the enzyme E20-7. To
assay the cocaine and benzoic acid concentrations in the blood samples, the frozen whole
blood samples were thawed on ice for 3 hours. Then 150 μl of mobile phase (26%
acetonitrile and 74% water containing 0.1% TFA) was mixed with each sample, and 50
μl of 10% HClO4 was added to break the blood cell membrane. The mixture was
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vortexed for 1 min and then centrifuged at 25,000 g for 15 min, and the supernatant was
transferred to an autosampler vial of which 200 μl was injected into the chromatographic
system. Chromatography was performed using a Waters 1525 binary HPLC pump
(Waters Corporation, Milford, MA), a Waters 2487 dual λ absorbance detector, a Waters
2475 multi λ fluorescence detector, and a Waters 717 plus autosampler. The flow rate
was 1 ml/min. The eluent was monitored at 230 nm for absorbance of benzoic acid and at
315 nm for fluorescence of cocaine while exciting at 230 nm. The cocaine peaks
appeared at 10.5 min, and the benzoic acid peaks occurred at 14.5 min. The
concentrations of cocaine and benzoic acid were determined by comparing the
corresponding HPLC peak areas with those of authentic standards.

5.3.2.2 Cocaine clearance accelerated by E20-7
In order to examine the in vivo potency of E20-7 for metabolizing cocaine, we
characterized the pharmacokinetic profiles of cocaine clearance in the absence or
presence of E20-7 in rats by using a chromatographic assay. The rats (n=4) were injected
with PBS, 0.01 or 0.02 mg/kg E20-7, followed by i.v. injection of 5 mg/kg cocaine. E207 can hydrolyze cocaine to produce benzoic acid and ecgonine methyl ester, and greatly
accelerate the clearance of cocaine from the body. It has been known that the endogenous
BChE in rats is very inefficient in metabolizing cocaine and, for this reason, cocaine was
mainly metabolized by liver carboxylesterase in the blood to produce benzoylecgonine
and methanol in rats.(99) E20-7 accelerated cocaine clearance dose-dependently as
depicted in Figure 5.2. The control curves in Figure 5.2 reflect the overall effects of the
all cocaine elimination pathways. In the control rats, the average concentration of cocaine
at the first time point (2 min) was 7.4 μM, while the average concentration of benzoic
acid (metabolite) was 0.5 μM. With a very low dose (0.01 mg/kg) of E20-7 pretreatment,
the initial cocaine peak (2.9 μM) was slightly lowered than the control (7.4 μM). When
the rats were given 0.02 mg/kg E20-7 prior to the cocaine challenge, the initial cocaine
concentration at 2 min was decreased to a very low level (0.6 μM). The corresponding
initial benzoic acid peak was elevated, indicating that the accelerated clearance is due to
the activity of administrated E20-7 in the plasma. The high potency of E20-7 for
metabolizing cocaine in rats is consistent with its high in vitro catalytic activity against
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cocaine. This E20-7 dose (0.02 mg/kg) used is lowered than the previously used dose of
E12-7 (0.1 mg/kg) (123) to produce the same effect.
It should be mentioned that the total plasma concentration of cocaine and benzoic
acid (~11.6 μM) in the presence of E20-7 (when the benzoic acid concentration was
higher) was higher than that (~7.6 μM) in the absence of E20-7 (when the cocaine
concentration was higher). This observation might be associated with the potentially
different distribution volumes of cocaine and benzoic acid in the body. As well known,
cocaine is an amine drug which can readily cross cell membranes under physiological
condition, while benzoic acid primarily exists in the benzoate ion under physiological
condition. So, benzoic acid is expected to have a relatively smaller distribution volume
compared to cocaine.
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(A)

(B)

Figure 5.2 Cocaine (i.v. administrated) clearance accelerated by E20-7. Time-dependent
concentrations of cocaine (A) and benzoic acid (B) in cocaine clearance accelerated by
E20-7 expressed in stable CHO-S cells. E20-7 or PBS was i.v. injected 1 min before 5
mg/kg cocaine i.v. administration (n=4). The blood was sampled from 2 to 60 min after
the injection of cocaine. The concentrations of cocaine in the blood samples were
quantitated in duplicate by using an HPLC.

The effect of E20-7 on acceleration of cocaine clearance was also evaluated in a
similar experiment, with cocaine being administrated through intraperitoneal injection.
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The rats (n=5) were injected with PBS or E20-7 through tail vein, followed by i.p.
injection of 25 mg/kg cocaine. Similar effects were observed as depicted in Figure 5.3. In
the control rats, cocaine concentration peaked (2.2 μM) at 15 min after i.p. cocaine
administration. With a very low dose (0.04 mg/Kg) of E20-7, the peak concentration of
cocaine was as low as 0.15 μM; when the dose of E20-7 was increased to 0.10 mg/Kg,
the peak concentration of cocaine was below the detectable level. The corresponding
benzoic acid concentration was elevated due to the treatment of E20-7. Two doses of
E20-7 gave the similar levels of benzoic acid, only differs in the peak time.

(A)

(B)
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Figure 5.3 Cocaine (i.p. administrated) clearance accelerated by E20-7. Time-dependent
concentrations of cocaine (A) and benzoic acid (B) in cocaine clearance accelerated by
E20-7 expressed in stable CHO-S cells. E20-7 or PBS was i.v. injected 1 min before 25
mg/kg cocaine i.p. administration (n=5). The blood was sampled from 5 to 150 min after
the injection of cocaine. The concentrations of cocaine in the blood samples were
quantitated in duplicate by using an HPLC.

To summarize, the E20-7-caused dramatic changes in both the cocaine and benzoic
acid concentrations clearly indicated that cocaine was rapidly metabolized to benzoic
acid in the presence of E20-7. The pretreatment of E20-7 greatly accelerate the clearance
of cocaine from the rats, no matter how cocaine is administrated. The high potency of
E20-7 in metabolism of cocaine correlates with its high catalytic activity against cocaine.
The minimum dose of E20-7 required to quickly clear cocaine from body is expected to
be lowered than that of E12-7 to produce the same effect.

5.3.3 Protection effects of E20-7 against acute toxicity of a lethal dose of cocaine
5.3.3.1 Animal procedure
Cocaine hydrochloride and purified enzyme E20-7 were prepared to the required
concentration and administered at a volume of 0.2 mL/mouse. Cocaine-induced acute
toxicity was characterized by the occurrence of convulsion and lethality. Cocaineinduced convulsion was defined as loss of righting posture for at least 5 sec with the
simultaneous presence of clonic limb movements (162). Lethality was defined as
cessation of observed movement and respiration.
CD-1 mice (male, 27-30 g) were used in this study. PBS or E20-7 at different doses
(n=6) was injected through tail vein 1 min before intraperitoneal administration of
cocaine 180 mg/kg (LD100). After administration of cocaine, mice were immediately
placed individually in cages for observation. The presence or absence of convulsions and
lethality were recorded for 60 min after cocaine administration.

5.3.3.2 Protection effects of E20-7
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The purified E20-7 was used to study their in vivo activity in protection of mice
from acute toxicity of a lethal dose of cocaine (180 mg/kg, LD100). As shown in Figure
5.4, for the control experiments without administration of the enzyme, intraperitoneal
(i.p.) administration of 180 mg/kg cocaine produced lethality in all tested mice (n=6).
Pretreatment with E20-7 (i.e. 1 min prior to cocaine administration) dose-dependently
protected mice against cocaine-induced convulsion and lethality. In particular, E20-7 at a
small dose of 0.2 mg/kg produced full protection in mice after receiving a lethal dose
(180 mg/kg) of cocaine. So, the minimum dose of the enzyme required to produce full
protection of the mice from the acute toxicity of 180 mg/kg cocaine was determined to be
0.2 mg/kg for E20-7. The minimum dose of E12-7 required to produce full protection of
the mice from 180 mg/kg cocaine induced acute toxicity is a dose between 0.33 mg/kg
and 1 mg/kg (76), therefore E20-7 is more potent than E12-7 in their practical protection
effects, which is consistent with their in vitro catalytic efficiencies against cocaine. The
in vivo data depicted in Figure 5.4 suggest that E20-7 is indeed promising for cocaine
detoxification in therapeutic treatment of cocaine abuse.
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Figure 5.4 Potency of protection effects of E20-7 against acute toxicity of a lethal dose of
cocaine. The PBS or E20-7 was administered i.v. 1 min before i.p. administration of 180
mg/kg cocaine (n=6). The asterisks represent significant differences from the conditions
of mice pretreated with PBS (p<0.05).
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5.3.4 Effects of E20-7 on the hyperactivity induced by cocaine
5.3.4.1 Animal procedure
The effect of E20-7 on cocaine-induced hyperactivity was evaluated by using a
video-tracking system at the University of Kentucky’s Rodent Behavior Core (RBC). The
locomotor activity test was performed in high density, non-porous plastic chambers
measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in a light- and sound-attenuating
behavioral test enclosure (San Diego Instruments, San Diego, CA). Cumulative distance
traveled and speed was recorded by EthoVision XT video tracking system (Noldus
Information Technology, Wageningen, Netherlands) to represent the locomotor activity.
The test session was 60 min long and data was collected in 5-min bins. Male Swiss
Webster mice were introduced to the test chambers for habituation (90 min long per
session) on two consecutive days before the test day. On the test day, mice were allowed
to acclimate to the test chambers for 60 minutes, and the total distance traveled during
this period of time was used to determine the basal activity. Then E20-7 or PBS was
administered through intravenous (i.v.) injection, followed by intraperitoneal (i.p.)
injection of 25 mg/kg cocaine or saline (n=8). After the cocaine/saline administration,
mice were immediately returned to the test chamber for activity monitoring in the
following session of 60 minutes.

5.3.4.2 Effects of E20-7 on the hyperactivity induced by cocaine
The potency of E20-7 in elimination of the physiological effects of cocaine was
evaluated in Male Swiss Webster mice. Based on the results shown in Figure 5.6,
compared with the baseline in the control group (treated with i.v. PBS and i.p. saline),
without pretreatment of E20-7, 25 mg/kg cocaine (i.p.) induced rather strong
hyperactivity in mice. The group injected with 0.04 mg/kg E20-7 still displayed slight
hyperactivity, but the extent and duration of hyperactivity were decreased considerably.
Furthermore, 0.10 mg/kg E20-7 completely eliminated the hyperactivity induced by 25
mg/kg cocaine, as seen in Figure 5.6. The minimum dose of E20-7 required to completely
suppress the hyperactivity induced by 25 mg/kg cocaine was 0.10 mg/kg.
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Figure 5.5 Effects of the exogenous enzyme E20-7 on cocaine-induced hyperactivity.
PBS or E20-7 was injected i.v. into mice through tail veins 1 min before i.p. injection of
saline or cocaine. Four groups were scheduled, and each group had eight mice (n=8).
Group A were treated with i.v. PBS and i.p. saline; Group B were treated with i.v. 0.04
mg/kg E20-7 and i.p. 25 mg/kg cocaine; Group C were treated with i.v. 0.10 mg/kg E207 and i.p. 25 mg/kg cocaine. Group D were treated with i.v. PBS and i.p. 25 mg/kg
cocaine.
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Volkow et al. reported that, for humans, ―at least 47% of dopamine transporter has
to be blocked for subjects to perceive cocaine’s effects‖(163). Cocaine diffuse across the
blood brain barrier is very fast so that there is an equilibrium distribution between plasma
and brain. The threshold concentrations of cocaine in human brain and plasma required to
produce physiological effects were estimated to be 0.220.07 µM and 0.24±0.08 µM,
respectively, in light of a recently reported cocaine pharmacokinetic modeling.(82) When
the cocaine concentration in brain and plasma do not reach the ―threshold‖ values
because of the administration of an efficient cocaine-metabolizing enzyme, one may
consider that the enzyme has effectively prevented cocaine from entering the brain and
producing the detectable physiological effects. The hyperactivity induced by cocaine
correlate with the corresponding plasma cocaine concentration. As shown in Figure 5.3,
with the pretreatment of 0.04 mg/kg E20-7, the blood cocaine concentrations in rats for
the first 15 min after cocaine administration were under ~0.2 μM, close to the threshold
value for humans. With the pretreatment of 0.10 mg/kg E20-7, the blood cocaine
concentrations in the investigated period were in a very low level (under ~0.05 μM),
which is much lower than the threshold value to produce measurable physiological
effects. So, 0.10 mg/kg E20-7 completely eliminated the hyperactivity induced by 25
mg/kg cocaine. Base on the above analysis, E20-7 has shown great potential in rapidly
accelerating cocaine metabolism in plasma and completely eliminating cocaine-induced
hyperactivity, indicating that E20-7 can effectively prevent cocaine from entering brain
and producing the physiological effects.

5.4 Conclusion
This study reveals that the newly discovered E20-7 is more active against cocaine
than E12-7 both in vitro and in vivo. The catalytic activity of E20-7 for cocaine
hydrolysis is considerably improved compared to the wild-type BChE, and comparable to
that of the most efficient hydrolytic enzyme AChE for ACh hydrolysis. Extensive in vivo
studies in rodents have demonstrated that administration of E20-7 can indeed rapidly
metabolize cocaine, can protect the mice from the acute toxicity induced by lethal dose of
cocaine, and efficiently prevent cocaine from entering brain and producing the
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physiological effects. In particular, the catalytic efficiency of the enzymes correlates with
their practical efficacy in cocaine detoxification. Therefore, the higher the catalytic
activity, the lower the dose required for effective detoxification, and the lower the cost
for treatment of cocaine abuse. E20-7 is identified as the most efficient cocaine hydrolase
at this point of time, and may be developed as a valuable therapeutic agent for cocaine
abuse treatment.

Copyright @ Shurong Hou 2014
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Chapter Six: Concluding Remarks and Future Plan

Human BChE has been recognized as a promising candidate of the enzyme therapy
to detoxify cocaine. However, the low activity of wide-type human BChE against cocaine
limits its potential therapeutic use in cocaine abuse treatment. Dr. Zhan’s lab previously
designed and discovered a series of high-activity mutants of human BChE. In particularly,
E12-7 has a 2000-fold improvement in catalytic efficiency against cocaine, compared to
wide-type BChE.
This dissertation was mainly focused to address the possible concerns in further
development of those promising BChE mutants for cocaine abuse treatment, such as
whether the administration of this exogenous enzyme will affect the cholinergic system,
whether it can efficiently hydrolyze the cocaine’s toxic metabolites, and whether the
commonly used therapeutic agents will significantly affect the catalytic activity of
designed BChE mutants against cocaine when they are co-administered. Both
computational modeling and experimental kinetic analysis on the catalytic activity of the
previously designed BChE mutants (includes E12-7) against the various substrates,
including acetylcholine (the only natural substrate in the body) and cocaine metabolite
cocaethylene, were carried out to demonstrate the substrate selectivity of BChE mutants
for cocaine and cocaethylene over acetylcholine. Meanwhile, possible drug-drug
interactions between the promising enzyme E12-7 and some commonly used agents were
investigated in vitro, providing insights for the further development of E12-7 into an
effective treatment for cocaine abuse. In addition, further computational design using
E12-7 as a standard reference was followed by extensive wet experimental tests,
including both in vitro and in vivo assays, leading to a more promising BChE mutant
E20-7. The identified mutants of human BChE are expected to be valuable candidates for
development of a more efficient enzyme therapy for cocaine abuse.

6.1 Summary of the major conclusions obtained from this investigation
1) Both the computational modeling and experimental kinetic analysis have
consistently revealed that all the examined BChE mutants in this study have a
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considerably improved catalytic efficiency against (-)-cocaine, without dramatically
improving the catalytic efficiency against any of the other examined substrates (including
acetylcholine, acetylthiocholine, butyrylthiocholine, and (+)-cocaine), compared to the
wild-type BChE. The previously designed BChE mutants showed desired selectivity for
(-)-cocaine over neurotransmitter acetylcholine.

2) Based on the obtained kinetic data, E14-3 and E12-7 have a considerably
improved catalytic activity against cocaethylene compared to the wild-type BChE. E12-7
is identified as the most promising enzyme for hydrolyzing for all three toxic compounds,
i.e. (-)-cocaine, cocaethylene, and norcocaine.

3) According to the in vitro drug-enzyme interaction data, most of the tested drugs
did not display significant inhibition on E12-7. However, some tricyclic antidepressants
(TCA) at high concentrations did inhibit the enzyme and, thus, should be avoided or used
with caution. Importantly, the current drugs for cocaine overdose treatment in the ED do
not affect the catalytic activity of E12-7 for cocaine hydrolysis.

4) The newly discovered mutant E20-7 is more active for cocaine than E12-7 both in
vitro and in vivo. The catalytic activity of E20-7 for cocaine hydrolysis is comparable to
that of the most efficient hydrolytic enzyme AChE for ACh hydrolysis. Extensive in vivo
studies in rodents have demonstrated the practical efficacy of E20-7 in cocaine
detoxification and the correlation between the practical efficacy and the in vitro catalytic
efficiency. E20-7 may be developed as a valuable therapeutic agent for cocaine abuse
treatment.

6.2 Future plan of this investigation
1) In vitro characterization of E20-7 against other potential substrates or for the
interactions with commonly used small-molecule drugs, as what we have done for E12-7
and other BChE mutants;
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2) Additional in vivo study in rodents is necessary in order to predict the likelihood
of drug-enzyme interactions in human;
3) Further development of human BChE mutants for cocaine addiction treatment
should be focused on improving the biological half-life while maintaining the high
catalytic activity against (-)-cocaine.
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